A neoplastic disease of the lymphoreticular cells which is considered to be a rare type of chronic leukemia; it is characterized by an insidious onset, splenomegaly, anemia, granulocytopenia, thrombocytopenia, little or no lymphadenopathy, and the presence of "hairy" or "flagellated" cells in the blood and bone marrow.
A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.
Nucleosides containing arabinose as their sugar moiety.
A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.
A group of 2-hydroxybenzoic acids that can be substituted by amino groups at any of the 3-, 4-, 5-, or 6-positions.
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Therapeutic act or process that initiates a response to a complete or partial remission level.
A chronic leukemia characterized by a large number of circulating prolymphocytes. It can arise spontaneously or as a consequence of transformation of CHRONIC LYMPHOCYTIC LEUKEMIA.
A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
A lymphoproliferative disorder characterized by pleomorphic B-LYMPHOCYTES including PLASMA CELLS, with increased levels of monoclonal serum IMMUNOGLOBULIN M. There is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. Clinical features include ANEMIA; HEMORRHAGES; and hyperviscosity.
Surgical procedure involving either partial or entire removal of the spleen.
2-Chloroadenosine. A metabolically stable analog of adenosine which acts as an adenosine receptor agonist. The compound has a potent effect on the peripheral and central nervous system.
The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.
The therapy of the same disease in a patient, with the same agent or procedure repeated after initial treatment, or with an additional or alternate measure or follow-up. It does not include therapy which requires more than one administration of a therapeutic agent or regimen. Retreatment is often used with reference to a different modality when the original one was inadequate, harmful, or unsuccessful.
Antibodies obtained from a single clone of cells grown in mice or rats.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Organic salts and esters of benzenesulfonic acid.
Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
The return of a sign, symptom, or disease after a remission.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
Remnant of a tumor or cancer after primary, potentially curative therapy. (Dr. Daniel Masys, written communication)
An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
A decrease in the number of NEUTROPHILS found in the blood.
The concentration of a compound needed to reduce population growth of organisms, including eukaryotic cells, by 50% in vitro. Though often expressed to denote in vitro antibacterial activity, it is also used as a benchmark for cytotoxicity to eukaryotic cells in culture.
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
A subnormal level of BLOOD PLATELETS.
Proteins secreted by vertebrate cells in response to a wide variety of inducers. They confer resistance against many different viruses, inhibit proliferation of normal and malignant cells, impede multiplication of intracellular parasites, enhance macrophage and granulocyte phagocytosis, augment natural killer cell activity, and show several other immunomodulatory functions.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin.
The giving of drugs, chemicals, or other substances by mouth.
A measure of the quality of health care by assessment of unsuccessful results of management and procedures used in combating disease, in individual cases or series.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
The action of a drug in promoting or enhancing the effectiveness of another drug.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
The relationship between the dose of an administered drug and the response of the organism to the drug.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.

Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse. (1/220)

PURPOSE: Cladribine (2-chlorodeoxyadenosine, 2-CdA) has been reported to be effective in the treatment of low-grade lymphomas. The objective of this multicenter study was to evaluate the activity of cladribine in mantle-cell lymphomas as first-line therapy or in first relapse using an intermittent two-hour infusion of cladribine. PATIENTS AND METHODS: A total of 47 courses, or an average of four courses per patient, were administered to 12 patients (seven untreated, five relapsed) with 5 mg/m2 cladribine given as an intermittent two-hour infusion over five consecutive days for a maximum of six cycles every four weeks. RESULTS: Cladribine showed activity in patients with mantle-cell lymphomas, achieving a response rate of 58% (95% confidence interval (95% CI): 28%-85%). Myelosuppression was the major toxicity with 17% of grade 3 and 4 neutropenia. Thrombocytopenia was rare with only 2% of grade 3 and 4. CONCLUSION: These results demonstrate single-agent activity of cladribine in mantle-cell lymphomas using the intermittent two-hour infusion dosage regimen. To further improve treatment results, cladribine should be combined with other agents active in mantle-cell lymphomas.  (+info)

Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications. (2/220)

BACKGROUND AND OBJECTIVE: It has been widely demonstrated that one single 7-day course continuous infusion (c.i.) 2-chlorodeoxyadenosine (2-CdA) at a dose of 0.1 mg/kg daily is dramatically effective in inducing high and prolonged complete remission (CR) rates in patients with hairy-cell leukemia (HCL). However, 2-CdA administration often results in severe neutropenia and lymphocytopenia both responsible for the infectious complications observed in these patients. We previously reported preliminary data regarding the effectiveness and toxicity of a modified protocol of 2-CdA administration (0.15 mg/kg 2 hours infusion once a week for 6 courses) in 25 HCL patients. This treatment schedule produced a similar overall response rate compared to standard 2-CdA regimen and appeared to be followed by a lower incidence of infectious episodes. In the present study we report response rate and toxicity of weekly 2CdA administration in a larger cohort of patients and with a longer follow-up. DESIGN AND METHODS: In a group of HCL patients with a pronounced decrease in neutrophils count (< 1 x 10(9)/L), we modified the standard protocol (0.1 mg/kg daily x 7 days c.i.) by administering 2-CdA at a dose of 0.15 mg/kg 2 hours infusion once a week for 6 courses. Thirty HCL patients, 24 males and 6 females with a median age of 56 years (range 37-76), entered into this protocol. Seventeen out of 30 patients were at diagnosis while the remaining 13 had been previously treated with alpha-interferon (alpha-IFN) (7), or 2-CdA (4) or deoxycoformycin (DCF) (2). RESULTS: Overall, 22/30 (73%) patients achieved CR and 8 (27%) partial remission (PR) with a median duration of response at the time of writing of 35 months, ranging from 6 to 58 months. Five patients (1 CR and 4 PR) have so far progressed. The treatment was very well tolerated. Five out of 30 patients (16%) developed severe neutropenia (neutrophils < 0.5 x 10(9)/L) and only in two of them we did register an infectious complication which required treatment with systemic antibiotics and granulocyte colony-stimulating factor (G-CSF). INTERPRETATION AND CONCLUSIONS: In conclusion, we confirm that weekly administration of 2-CdA at a dose of 0.15 mg/kg for 6 courses appears to be very effective in HCL inducing a high CR rate, similar to that observed with daily c.i. administration. CR durability and relapse/progression rates are also comparable to standard 2-CdA schedule. Moreover this new regimen seems to be safer in pancytopenic patients, markedly reducing life-threatening infectious complications.  (+info)

Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies. (3/220)

The feasibility of combining cladribine with cyclophosphamide and prednisone in the management of indolent lymphoid malignancies was determined. Nineteen patients [nine chronic lymphocytic leukaemia (CLL), seven non-Hodgkin's lymphoma (NHL) and three macroglobulinaemia (M))] received cladribine 0.1 mg kg(-1) per day as a subcutaneous bolus injection on days 1-3 (up to 5 injections) with intravenous cyclophosphamide 500 mg m(-2) on day 1 and oral prednisone 40 mg (m-2) on days 1-5 at 4-weekly intervals up to a maximum of six courses. A total of 80 courses were given. Overall response rate was 88%, with four patients achieving a complete clinical and haematological response and 12 achieving a partial response. Neutropenia WHO grade 4 in two patients and WHO grade 3 infection in one patient were the limiting toxicities on treatment. During the follow-up, WHO grade >3 haematological complications occurred in five patients and WHO grade >3 non-haematological complications in five patients. There were no treatment-related deaths. This study demonstrates the feasibility of the cladribine/cyclophosphamide/prednisone (CCP) combination that appears highly active and safe in the management of indolent lymphoid malignancies.  (+info)

Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. (4/220)

Cladribine treatment of hairy cell leukemia (HCL) is complicated by neutropenic fever in 42% of patients despite documented infections being relatively uncommon. We performed a study of priming filgrastim followed by cladribine and then filgrastim again to determine if filgrastim would lead to a reduction of neutropenia and febrile episodes. Thirty-five patients received filgrastim and cladribine and were compared with 105 historic controls treated with cladribine alone. Cladribine was administered at 0.1 mg/kg/d by continuous infusion for 7 days. Filgrastim was administered at 5 micrograms/kg/d subcutaneously on days -3, -2, and -1 and then again after the completion of cladribine until the absolute neutrophil count (ANC) was >/=2 x 10(9)/L on 2 consecutive days (days +8, +9, etc). After filgrastim priming, the median ANC increased from 0.9 x 10(9)/L to 2.26 x 10(9)/L (2.5-fold increase), and after cladribine, the median nadir ANC in the filgrastim-treated group was 0.53 x 10(9)/L compared with 0.29 x 10(9)/L among historic controls (P =. 04). The median number of days to an ANC greater than 1.0 x 10(9)/L was 9 days in the filgrastim-treated group versus 22 days among historic controls (P < 10(-5)). The percentage of febrile patients, number of febrile days, and frequency of admissions for antibiotics were not statistically different in the two groups. Filgrastim regularly increases the ANC in patients with HCL and shortens the duration of severe neutropenia after cladribine. This phase II study, with comparison to historical controls, failed to detect any clinical advantage from the use of filgrastim and cladribine in the treatment of HCL. Accordingly, the routine adjunctive use of filgrastim with cladribine in the treatment of HCL cannot be recommended.  (+info)

Cladribine activity in adult langerhans-cell histiocytosis. (5/220)

Langerhans-cell histiocytosis (LCH) results from the accumulation of tissue histiocytes derived from the same progenitor cells as monocytes. Because cladribine is potently toxic to monocytes, we conducted a phase II trial of cladribine. Cladribine was administered to 13 LCH patients at 0.14 mg/kg per day by 2-hour intravenous infusion for 5 consecutive days, every 4 weeks for a maximum of six courses. Median age was 42 years (range, 19 to 72) and median pretreatment disease duration was 99 months (range, 6 to 252). One patient was untreated, one had received prior prednisone only, one prior radiation only, six prior radiation and chemotherapy, and four prior surgery, radiation, and chemotherapy. Seven patients had cutaneous involvement, six multifocal osseous, six pulmonary, two each with soft tissue and nodal involvement, and four had diabetes insipidus. Of 13 patients, 12 were evaluable for response and all for toxicity. After a median of three courses (range, 1 to 6), seven (58%) patients achieved complete responses (two pathologic and five clinical) and two (17%) patients achieved partial responses; overall response rate, 75%. Median response follow-up duration was 33 months (range, 1 to 65). Seven patients experienced grade 3 to 4 neutropenia. Only one patient had a documented infection, dermatomal herpes zoster. At a median follow-up of 42 months (range, 5 to 76), 12 patients remain alive and one patient has died. Thus, cladribine has major activity in adult LCH and warrants further investigation in both pediatric and adult LCH as a single agent and in combination with other drugs.  (+info)

Basic fibroblast growth factor is expressed by CD19/CD11c-positive cells in hairy cell leukemia. (6/220)

Several features are characteristic for hairy cell leukemia (HCL). Among those are pancytopenia, bone marrow fibrosis, and the appearance of a defined tumor cell phenotype in peripheral blood (PB), bone marrow (BM), and spleen. Hairy cells (HC) coexpress antigens specific for B lymphocytes and monocytes/macrophages and thus the malignant cell does not seem to be restricted to a defined lineage. When serum or bone marrow aspirate was screened by enzyme-linked immunosorbent assay (ELISA) for basic fibroblast growth factor (bFGF), specimen derived from HCL (serum: mean value, 29 pg/mL; BM aspirate: mean value, 641 pg/mL) contained significantly higher levels than those from healthy subjects. To study whether peripheral blood mononuclear cells (PBMC) derived from patients suffering from HCL and healthy donors (HD) were capable of producing bFGF, culture supernatant (conditioned medium, [CM]) was tested for the presence of this cytokine. While bFGF was not detectable in cell cultures from HD, HCL-derived CM contained relatively high levels of bFGF. CM was successfully used for stimulation of mesenchymal cell proliferation, which could be inhibited by a neutralizing anti-bFGF antibody. Cellular activation by pokeweed mitogen (PWM) or the combination of 12-o-tetradecanoyl-phorbol-13-acetate (TPA) plus calcium ionophore (Ca-Ip) led to an enhanced mRNA expression. Results of Western blot experiments showed that HC synthesize at least three isoforms (approximately 18, 23, and 25 kD), but only the 23-kD isoform is exported. To assess the nature of the producer cell, double immunofluorescence analysis using a bFGF-specific and an anti-CD11c monoclonal antibody (MoAb) was undertaken. The majority of cells scoring positive for CD11c were also reactive with the anti-bFGF MoAb. Furthermore, enrichment of CD19/CD11c-positive cells correlated with enhanced bFGF levels, thereby supporting the argument for HC being the producer cells of bFGF. A biological function of bFGF in HCL might be mediation of chemoresistance, as 2-chlorodeoxyadenosine (2-CdA)-induced inhibition of cell proliferation can be reversed by bFGF. Endogenous bFGF production by HC is not affected by this purine analogue and 2-CdA-induced apoptosis is diminished in bFGF-producing HC as compared with normal PBMC. Therefore, bFGF expression by HC might be important for resistance to chemotherapy and survival of the malignant cells.  (+info)

Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse. (7/220)

The purine nucleoside analogues 2-chlorodeoxyadenosine (2-CdA) and 2'-deoxycoformycin (2'-DCF) induce complete remission (CR) in the majority of patients with hairy cell leukemia. However, minimal residual disease (MRD) has been detected in bone marrow core biopsies using immunohistochemical techniques in patients achieving CR by conventional criteria. This study was designed to compare the prevalence of MRD with each agent in patients in CR by using conventional criteria and the relapse-free survival for patients with and without MRD. Bone marrow biopsies from 39 patients treated with a single cycle of 2-CdA and 27 patients treated with multiple cycles of 2'-DCF were studied. The monoclonal antibodies anti-CD20, DBA.44, and anti-CD45RO were used to evaluate the paraffin-embedded bone marrow core biopsies for MRD. Five of 39 patients (13%) treated with 2-CdA had MRD, as compared to 7 of 27 patients (26%) treated with 2'-DCF (two-tailed P = 0.21). Relapse has occurred in two of the five patients with MRD after 2-CdA treatment and in four of the seven patients with MRD after 2'-DCF treatment. In total, 6 of the 12 patients (50%) with MRD have relapsed, whereas 3 of 54 patients (6%) without MRD have relapsed, and 2 patients have died without evidence of relapse. The estimated 4-year relapse-free survival among patients with MRD is 55% (+/- 15%, SE), compared to 88% (+/- 5%, SE) among patients without MRD (two-tailed P = 0.0023). The prevalence of MRD detected in a subset of patients in CR after either 2-CdA or 2'-DCF treatment did not differ significantly. However, the presence of MRD is associated with an increased risk of relapse.  (+info)

Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. (8/220)

The objective of the present study was to investigate the biochemical pharmacology of 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine (CAFdA)--a fluorinated analogue of cladribine [2-chloro-2'-deoxyadenosine, Leustatin (CdA)] with improved acid and metabolic stability--in human leukemic cell lines and in mononuclear cells isolated from patients with chronic lymphocytic leukemia (CLL) and acute myelocytic leukemia (AML). We have also made and characterized two cell lines that are not sensitive to the growth inhibitory and cytotoxic effects of CAFdA. Incubation of cells isolated from the blood of CLL and AML patients with various concentrations of CdA or of CAFdA accumulated CdA and CAFdA nucleotides in a dose-dependent manner. A significantly higher rate of phosphorylation to monophosphates was observed for CAFdA than for CdA in cells from CLL patients (n = 14; P = 0.04). The differences in the phosphorylation were even more pronounced for the respective triphosphates in both CLL (n = 14; P = 0.001) and AML (n = 4; P = 0.04) cells. Retention of CAFdA 5'-triphosphate (CAFdATP) was also longer than that for CdA 5'-triphosphate (CdATP) in cells from leukemic patients. The relative efficacy of CAFdA as a substrate for purified recombinant deoxycytidine kinase (dCK), the key enzyme in the activation of nucleoside analogues, was very high and exceeded that of CdA as well as the natural substrate, deoxycytidine, by a factor of 2 and 8, respectively. The Km for CAFdA with dCK was also lower than that for CdA, as measured in crude extracts from the human acute lymphoblastic leukemia cell line CCRF-CEM and the promyelocytic leukemia cell line HL60. Acquired resistance to CAFdA in HL60 and in CCRF-CEM cell lines was directly correlated to the decreased activity of the nucleoside phosphorylating enzyme, dCK. Resistant cells also showed a considerable degree of cross-resistance to analogues that were activated by dCK. These observations demonstrated that dCK phosphorylates CAFdA more efficiently than CdA. Furthermore, CAFdATP is apparently more stable than CdATP and the mechanisms of resistance to CAFdA are similar to those leading to CdA resistance. These results encourage studies on the clinical effect of CAFdA in lymphoproliferative diseases.  (+info)

TY - JOUR. T1 - 2-Chlorodeoxyadenosine in cutaneous T-cell lymphoproliferative disorders. AU - Kong, Lynn R.. AU - Samuelson, Ellen. AU - Rosen, Steven T.. AU - Roenigk, Henry H.. AU - Tallman, Martin S.. AU - Rademaker, Alfred W.. AU - Kuzel, Timothy M.. PY - 1997/1/1. Y1 - 1997/1/1. KW - 2-Chlorodeoxyadenosine. KW - Cutaneous T-cell lymphoma. KW - Mycosis fungoides. KW - Purine analog. UR - http://www.scopus.com/inward/record.url?scp=0030802833&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0030802833&partnerID=8YFLogxK. U2 - 10.3109/10428199709109162. DO - 10.3109/10428199709109162. M3 - Article. C2 - 9250792. AN - SCOPUS:0030802833. VL - 26. SP - 89. EP - 97. JO - Leukemia and Lymphoma. JF - Leukemia and Lymphoma. SN - 1042-8194. IS - 1-2. ER - ...
TY - JOUR. T1 - Outcome of pediatric patients with Langerhans cell histiocytosis treated with 2 chlorodeoxyadenosine. T2 - A nationwide survey in Japan. AU - Imamura, Toshihiko. AU - Sato, Takashi. AU - Shiota, Yoko. AU - Kanegane, Hirokazu. AU - Kudo, Kazuko. AU - Nakagawa, Shinichirou. AU - Nakadate, Hisaya. AU - Tauchi, Hisamichi. AU - Kamizono, Junji. AU - Morimoto, Akira. PY - 2010/5. Y1 - 2010/5. N2 - The aim of this study was to assess the outcome of treatment with 2-chlorodeoxyadenosine (2-CdA) in pediatric patients with Langerhans cell histiocytosis (LCH) in Japan. We retrospectively identified 17 pediatric LCH patients treated with 2-CdA. All patients were refractory or reactivated cases who had been initially treated according to the JLSG-02 protocol of the Japan LCH study group. At initiation of 2-CdA therapy, 4 patients had primary refractory multisystem (MS) disease with risk organ (RO) involvement (MS?), 9 patients had reactivated MS disease [5 MS+ and 4 without RO involvement ...
Greaver, MR. How I treat hairy cell leukemia. Blood. vol. 115. 2010. pp. 21-28. [Dr Greaver reviews the clinical features of hairy cell leukemia and the key treatment options.] Greaver, MR, Lozanski, G. Modern strategies for hairy cell leukemia. J Clin Oncol. vol. 29. 2011. pp. 583-590. [This is an update of the various treatment options, both standard and experimental, for hairy cell leukemia.] Robak, T. Current treatment options in hairy cell leukemia and hairy cell leukemia variant. Cancer Treat Rev. vol. 32. 2006. pp. 365-376. [This is an excellent review summarizing the different treatment options for both hairy cell leukemia and hairy cell leukemia variant.] Matutes, E, Wotherspoon, A, Brito-Babapulle, V, Catovsky, D. The natural history and clinico-pathologic features of the variant form of hairy cell leukemia. Leukemia. vol. 15. 2001. pp. 684-693. [This is an important and seminal review of the pathologic and clinical features of the variant form of hairy cell leukemia.] Thomas, ...
The targeted agent, Zelboraf® (vemurafenib), which is approved for the treatment of melanoma, provided high anti-cancer activity among patients with hairy-cell leukemia that had stopped responding to prior therapies. These results were recently published in the New England Journal of Medicine.. Hairy-cell leukemia is a type of cancer in which too many abnormal immune cells are produced. It is considered a slow-growing type of leukemia that occurs more commonly in older men. The cancer cells have a hairy appearance under the microscope.. A genetic mutation referred to as the BRAF V600E mutation is thought to be an involved the excessive replication of hairy cell leukemia, as it is a common mutation in this type of cancer. Zelboraf binds to a specific site in cells that blocks the excessive replication caused by the BRAF V600E mutation.. Researchers from Italy and the United States conducted clinical trials to evaluate Zelboraf among patients with hairy cell leukemia that had stopped responding ...
Symptoms of Hairy cell leukemia including 13 medical symptoms and signs of Hairy cell leukemia, alternative diagnoses, misdiagnosis, and correct diagnosis for Hairy cell leukemia signs or Hairy cell leukemia symptoms.
1. Cawley JC, Burns GF, Hayhoe FG. A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia. Leuk Res. 1980;4(6):547-59 2. Matutes E, Wotherspoon A, Catovsky D. The variant form of hairy-cell leukaemia. Best Pract Res Clin Haematol. 2003;16(1):41-56 3. Robak T. Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment. Cancer Treat Rev. 2011;37(1):3-10 4. Matutes E, Martínez-Trillos A, Campo E. Hairy cell leukaemia-variant: Disease features and treatment. Best Pract Res Clin Haematol. 2015;28(4):253-63 5. Jain P, Pemmaraju N, Ravandi F. Update on the biology and treatment options for hairy cell leukemia. Curr Treat Options Oncol. 2014;15(2):187-209 6. Swerdlow S, Campo E, Harris NL. et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th ed.). Lyon: International Agency for Research on Cancer (IARC). 2008:188-90 7. Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP. et al. BRAF ...
On September 13, the Food and Drug Administration approved moxetumomab pasudotox-tdfk (Lumoxiti, AstraZeneca) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. Lumoxiti is a CD22-directed cytotoxin and is the first of this type of treatment for patients with HCL ...
TY - JOUR. T1 - Flow cytometry in hairy cell leukemia before and during interferon alfa‐2b therapy. AU - Vokes, Everett E.. AU - Bitter, Mitchell A.. AU - Ratain, Mark J.. AU - Prystowsky, Michael B.. AU - Daly, Karen. AU - Golomb, Harvey M.. PY - 1987/6/15. Y1 - 1987/6/15. N2 - Mononuclear cells from 15 patients with hairy cell leukemia were studied before and during therapy with interferon alfa‐2b (IFN) by regular peripheral blood differential counts and flow cytometry, using a panel of monoclonal antibodies (Moab). Seven leukemic phase patients (Group 1) had a mean leukocyte count of 48,870/μl at entry with a mean absolute hairy cell (HC) count of 40,100/μl. After 3 months on IFN, both parameters decreased significantly (WBC 3,500/μl; HC count 130/μl). In eight patients with a cytopenic form of the disease (Group 2) the mean leukocyte count rose from 2950/μl to 3890/μl while the mean absolute HC count decreased from 300/μl to 120/μl. The morphologic shifts correlated well with ...
TY - JOUR. T1 - Activation of deoxycytidine kinase by inhibition of DNA synthesis in human lymphocytes. AU - Csapó, Z.. AU - Sasvári, M.. AU - Spasokoukotskaja, T.. AU - Talianidis, Iannis. AU - Eriksson, Staffan. AU - Staub, M.. PY - 2001/1/15. Y1 - 2001/1/15. N2 - Deoxycytidine kinase (dCK, EC.2.7.1.74) is a key enzyme in the intracellular metabolism of 2-chlorodeoxyadenosine, 1β-D-arabinofuranosylcytosine, difluorodeoxycytidine, and other drugs used in chemotherapy of different leukaemias and solid tumours. Recently, stimulation of dCK activity was shown by these analogues and by other genotoxic agents such as etoposide and NaF, all of which cause severe inhibition of DNA synthesis in cell cultures. Here we describe that direct inhibition of DNA polymerases by aphidicolin stimulated dCK activity in normal lymphocytes and acute myeloid leukaemic cells, as well as in HL 60 promyelocytic cell cultures. Increased dCK activity was not due to new protein synthesis under our conditions, as ...
Hairy cell leukemia (DBA.44) antibody recognizes an unknown, fixation-resistant antigen that is expressed in normal mantle zone B-cells. It may be expressed in endothelial cells, monocytoid B cells, and scattered immunoblasts as well. It is characteristically expressed in hairy cell leukemia, as well as a subset of marginal zone lymphomas, and may be useful is classification of these lymphomas.. ...
Hairy cell leukemia is a rare type of cancer of blood which is caused due to abnormal growth of B cells. Hairy cell leukemia (HCL) is called so as the outg
Hairy cell leukemia is a rare type of cancer of blood which is caused due to abnormal growth of B cells. Hairy cell leukemia (HCL) is called so as the outg
What is Hairy Cell Leukemia? Get the facts about Hairy Cell Leukemia symptoms, testing, treatment and care options from trusted sources.
[Therapeutic aspects in the management of hairy cell leukemia].: We searched Medline, Pascal, and Current Contents for literature on the treatment of hairy cell
Hairy cell leukemia (HCL) is an indolent B-cell neoplasm that strongly expresses CD20. Despite initial very high response rates with cladribine (Leustatin), many patients ultimately relapse.
What is hairy cell leukemia - I had blood work done red blood cells white blood cells and platelets were all low also hemocrit among others does this indicate leukemia? Maybe. At your age, leukemia usually shows a high white count. However, anemia is ALWAYS serious and worth investigating. WBC and platelets values only somewhat out of range are less worrisome. Im betting we find something treatable.
Hairy cell leukemia (HCL) is a rare cancer in adults that is usually found during testing for a low blood count. Read more about what doctors at MSK are looking for when they diagnose HCL.
Proliferation and cytogenetic analysis of hairy cell leukemia upon stimulation via the CD40 antigen.: Using the CD40 system, in vitro proliferation of hairy cel
Hairy Cell Leukemia Diagnosis (costs for program #35009) ✔ Academic Hospital Nordwest ✔ Department of Oncology and Hematology ✔ BookingHealth.com
Hairy Cell Leukemia Diagnosis (costs for program #144157) ✔ Academic Hospital Harlaching ✔ Department of Hematology, Oncology and Palliative Medicine ✔ BookingHealth.com
Reversine, a purine analog, experienced been proved that it could induce dedifferentiation of differentiated cells into multipotent progenitor cells. acid-Schiff staining assay in hepatogenic differentiated … Manifestation of pluripotent guns and epigenetic guns To further characterize the pluripotency of reversine-pretreated cells, manifestation of specific guns 468-28-0 supplier (April4, Sox2 and Nanog) of pluripotent cells were analyzed by using RT-PCR, western blotting and immunofluorescence. In addition, we also desired to determine which gene caused the differential strength. The outcomes indicated that reversine elevated the reflection of March4 significantly, but Sox2 and Nanog had been not really discovered (Fig. ?(Fig.5,5, A and B), which indicated the account activation of Oct4 performs a major function in order of 468-28-0 supplier cell pluripotency. Remarkably, upon reversine removal after 8 times, reversine-treated fibroblasts steadily came back to primary phenotype and the ...
FD65F7217BBE656C449A0090 Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit Thank you very much for your comments, We are using: DBA.44 from Dako catalog # M880. No pretreatment. Primary antibody dilution of 1:15 for 2 hours at RT, detection on the Ventana using the basic DAB kit. TRAP from Zymed catalog # 18-0199. HIER in citrate buffer pH 6.0. Primary antibody dilution of 1:100 for 1 hour at RT, detection on the Ventana using the basic DAB kit. DBA 44 dose not work on NexES. If they do Antigen Retrieval and incubate off line 30 min 1:25 -1:50 it works ok. DAKO does carry a Hairy Cell Leukemia marker (M0880). We have not tested it on the NeXES, but it should work in theory. Please contact DAKO We use the DBA.44 clone from Dako with a citrate buffer pretreatment at a dilution of 1:50. I do not know about using on the Nexes, as I have no experience with that instrument. The only antibody of which I am aware for Hairy Cell Leukemia is is DBA-44 but I do not recommend it ...
Hairy cell leukemia is a cancer of the blood. In hairy cell leukemia bone marrow produces too many lymphocytes, a white blood cell. This disease is rare and has a slow progression. The name hairy cells is derived from the abnormal villi - fine projections from the surface of the lymphocytes. When the cells increase,…
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if giving cl
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market. ...
We offer clinical cancer updates, treatment guidance, and research news to the oncology nursing community. Visit us often for drug therapy testing results, patient care information and more. Download our FREE app today.
This drug pipelines features 11 companies, including Astellas Pharma Inc, Novartis AG, ARA Healthcare Pvt Ltd, Cellectis SA, Incyte Corp, F. Hoffmann, AbbVie Inc
This page was last edited 18:00, 30 October 2015 by Haytham Allaham. Based on work by Kalsang Dolma, Lakshmi Gopalakrishnan, Michael Maddaleni, Varun Kumar, C. Michael Gibson, Jinhui Wu, Cafer Zorkun, Erin Lord and Jacki Buros (bot), wikidoc user and wikidoc anonymous user WhatamIdoing ...
(2-5)-3-deoxyadenosine triphosphate-3-deoxyadenosine monophosphate: dimers & trimers of the (p3dA) part of above cpd were also synthesized in first source
Burghaus L, Schütz U, Krempel U, De Vos RA, Jansen Steur EN, Wevers A, Lindstrom J, Schröder H. Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients ...
Hairy cell leukemia is an uncommon hematological malignancy characterized by an accumulation of abnormal B lymphocytes. It is usually classified as a sub-type of chronic lymphocytic leukemia (CLL). Hairy cell leukemia makes up approximately 2% of all leukemias, with fewer than 2,000 new cases diagnosed annually in North America and Western Europe combined. Hairy cell leukemia was originally described as histiocytic leukemia, malignant reticulosis, or lymphoid myelofibrosis in publications dating back to the 1920s. The disease was formally named leukemic reticuloendotheliosis and its characterization significantly advanced by Bertha Bouroncle and colleagues at The Ohio State University College of Medicine in 1958. Its common name, which was coined in 1966, is derived from the hairy appearance of the malignant B cells under a microscope. In hairy cell leukemia, the hairy cells (malignant B lymphocytes) accumulate in the bone marrow, interfering with the production of normal white blood cells, ...
The initial therapies of choice for hairy cell leukemia are either cladribine (2-chlorodeoxyadenosine, 2-CdA) or pentostatin. [1] [2] These drugs have comparable response rates but have not been compared in phase III trials. Cladribine is administered as a one-time continuous infusion or series of subcutaneous injections and is associated with a high rate of febrile neutropenia. [3] [4] [5] [6] Rarely, more than one course of treatment is required to induce a desirable response. Treatment should be discontinued once complete remission or stable partial remission with normalization of peripheral blood counts is reached. The presence of residual disease may be predictive of relapse but does not seem to affect survival. [5] [7] The role of consolidation or maintenance therapy in preventing relapse or progression of the disease after treatment with purine analogs has not been evaluated and remains unproven. Pentostatin is administered intermittently for a longer time but may result in a lower ...
Rosai-Dorfman disease (RDD) or sinus histiocytosis with massive lymphadenopathy is a rare lymphoproliferative disorder of unknown etiology. The disease usually presents with painless lymphadenopathy with occasional extranodal involvement in various organs. We report a case of a 36-year-old man wit …
Approval of LUMOXITI, a first-in-class medicine for hairy cell leukemia, marks first new treatment option for patients in over 20 years. AstraZeneca and MedImmune, its global biologics research and development arm, announced today that the US Food and Drug Administration (FDA) has approved LUMOXITI™ (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. LUMOXITI is not recommended in patients with severe renal impairment (CrCl ≤ 29 mL/min). The Phase III trial results demonstrated 75% (95% confidence interval [CI]: 64, 84) of patients receiving LUMOXITI achieved an overall response; 30% (95% CI: 20, 41) had a durable complete response.. Dave Fredrickson, Executive Vice-President, Global Head Oncology Business Unit, said: Todays FDA approval of LUMOXITI represents a significant milestone for people living with hairy ...
Pentostatin (Nipent) has demonstrated significant activity as a single agent in patients with low-grade B- and T-cell lymphomas, but thus far, clinical experience with combinations of pentostatin and other agents is limited. A study
To the Editor: Purine analogues, including cladribine (2-chlorodeoxyadenosine), are increasingly used in the treatment of Waldenstroms macroglobulinemia and other hematologic cancers. (1) Cladribine can cause profound immunosuppression, lymphopenia, and increased susceptibility to opportunistic infections. (2) We report on a patient with Waldenstroms macroglobulinemia in whom an Epstein-Barr virus (EBV)-associated diffuse large-cell lymphoma developed after treatment with cladribine. A 69-year-old woman received the diagnosis of Waldenstroms macroglobulinemia with IgM kappa in 1991. Because of the progression of the disease, treatment with standard doses of cladribine was initiated in June 1994 and repeated in August 1994. The patient had a remarkable response, with alleviation of her symptoms and more than 90 percent reduction of the serum paraprotein level. Five months after the completion of treatment with cladribine, pain developed in the right hip, and a right acetabular lytic lesion was ...
Background:. Hairy cell leukemia (HCL) is highly responsive to but not curable by cladribine (CdA). HCL responds to rituximab, which is not yet standard therapy for HCL.. Patients with the CD25-negative variant (HCLv) respond poorly to initial cladribine but do respond to rituximab in anecdotal reports.. Purine analogs cladribine and pentostatin have similar efficacy for HCL, both inhibiting DNA synthesis selectively in HCL cells. Cladribine is effective after just 1 cycle. Rituximab is an anti-CD20 monoclonal antibody which induces apoptosis and either complement or antibody dependent cytotoxicity (ADCC or CDC).. Patients in complete remission (CR) to cladribine have minimal residual disease (MRD) by immunohistochemistry of the bone marrow biopsy (BMBx IHC), a risk for early relapse. Tests for HCL MRD in blood or marrow include flow cytometry (FACS) or PCR using consensus primers. The most sensitive HCL MRD test is real-time quantitative PCR using sequence-specific primers (RQ-PCR).. In studies ...
Hairy cell leukemia (HCL) is a rare mature B-cell lymphoid malignancy that is listed as a distinct entity in the World Health Organization (WHO) classification of lymphohemopoietic tissues.1 Characteristically, HCL occurs in older patients (median age about 60 years) with male predominance (male:female ratio = 4:1) and usually presents with pancytopenia and monocytopenia associated with hepatosplenomegaly in the absence of lymph node enlargement.1 This clinical presentation reflects the marked infiltration of bone marrow (BM), spleen, and liver (usually with sparing of lymph nodes) by leukemic cells with wide cytoplasm and long, slender cell-surface projections. This hairy morphology can be appreciated only by careful examination of smear preparations and gives the disease its vivid, descriptive name.2 The HCL cells are positive for the B-cell-associated antigens CD19, CD20, and CD22 and typically coexpress the CD103, CD25, and CD11c molecules.1 As compared to other lymphoid malignancies, HCL ...
Hairy cell leukemia (HCL) is a chronic lymphoid leukemia, originally described in 1958 by Bouroncle and colleagues{ref1}{ref2} and named after the hairlike cytoplasmic projections seen on the sur... more
Hairy cell leukemia (HCL) is a chronic lymphoid leukemia, originally described in 1958 by Bouroncle and colleagues and named after the hairlike cytoplasmic projections seen on the surface of the abnormal B-cells (see the image below).{file36451}See Chronic Leukemias: 4 Cancers to Differentiate, a Critical Images slideshow, to help detect chro...
Robert J. Kreitman, MD, chief, Clinical Immunotherapy Section, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, discusses the findings of moxetumomab pasudotox as a treatment for patients with relapsed/refractory hairy cell leukemia.
Learn more about Hairy Cell Leukemia at LewisGale Regional Health System DefinitionCausesRisk FactorsSymptomsDiagnosisTreatmentPreventionrevision ...
Although the purine analogue, fludarabine, has not been approved by the National Institute for Clinical Excellence for first line use in CLL in England and Wales, its use, either alone or in combination, has become the standard of care in most other countries. A meta-analysis [Steurer M, Pall G, Richards S, Schwarzer G, Bohlius J, Greil R; on behalf of the Cochrane Haematologic Malignancies Group.Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis. Cancer Treat Rev. 2006 ;32:377-89] looked at five trials with 1838 patients randomized between an alkylator-based regimen and a purine analogue. Patients treated with a purine analogue had significantly higher overall and complete response rates, and longer progression-free survivals, that those treated with alkylator-based regimens, but overall survival was not significantly different. Three further large trials had not been evaluated at the time of analysis and we may yet see a ...
The potential role of AKT/mTOR signalling proteins and its association with the Raf-MEK-ERK pathway was investigated in hairy cell leukaemia (HCL). BRAFV600E expression and activated forms of AKT, mTOR, ERK1/2, p70S6k and 4E-BP1 were immunohistochemically assessed in 77 BM biopsies of HCL patients and correlated with clinicopathological and BM microvascular characteristics, as well as with c-Caspase-3 levels in hairy cells. Additionally, we tested rapamycin treatment response of BONNA-12 wild-type cells or transfected with BRAFV600E. Most HCL cases expressed p-p70S6K and p-4E-BP1 but not p-mTOR, being accompanied by p-ERK1/2 and p-AKT. AKT/mTOR activation was evident in BONNA-12 cells irrespective of the presence of BRAFV600E mutation and was implicated in cell proliferation enhancement. In multivariate analysis p-AKT/p-mTOR/p-4E-BP1 overexpression was an adverse prognostic factor for time to next treatment conferring earlier relapse. When p-AKT, p-mTOR and p-4E-BP1 were examined separately only p-4E
Street prednisolone lilly 20mg preisvergleich in zu. Product is fine and arrived quickly, all the way to the UK! «Developing the Purine Nucleoside Analogue Acyclovir: the Work of Gertrude B? These studies have all been completed, generic cialis vs brand cialis reviews but results are pending? Made to be worn over the hoop, enrico prandin commercialista adding graceful fullness and keeping the bones of the hoop skirt from showing through? In sometimes dostinex online uk case of adults with initial episodes of genital herpes, the dosage will be 1 gram to be taken two times daily for about 10 days. Further, cialis usa the fact that a veniremember would hold the State to a higher burden of proof is a race-neutral reason for striking that veniremember! Bei entsprechender Behandlung überleben vier von fünf Patienten diese Komplikation! Now jazzily kytril cost its fall, I take 450mg, by winter Ill be at 600mg! Far the easier but psychological support is equally important for successful outcome. ...
Umbelliprenin and Chronic Lymphocytic Leukemia (CLL) Treatment, Umbelliprenin and Chronic Lymphocytic Leukemia (CLL) Treatment, Responses of CLL cells to purine analogs with cyclophosphamide, Responses of CLL cells to purine analogs with cyclophosphamide, Advances in Chronic Lymphocytic Leukemia,
Cancer Therapy Advisor provides oncologists and oncology specialists with the latest information to correctly diagnose the latest cancer conditions, recommend procedures and guides. Visit often for updates and new information.
Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions ...
Free, official coding info for 2018 ICD-10-CM C91.4 - includes detailed rules, notes, synonyms, ICD-9-CM conversion, index and annotation crosswalks, DRG grouping and more.
This is a XML Sitemap which is supposed to be processed by search engines which follow the XML Sitemap standard like Ask.com, Bing, Google and Yahoo ...
Patients with chronic lymphocytic leukemia more likely to have similar DNA changes in up to six genes compared to people who do not have the cancer
Read information for childhood blood cancer patients and their families. Research treatments, side effects, and long-term care for child patients here.
We understand the worry and confusion that come with a diagnosis of cancer. In addition to superior medical care and the latest technology, Roswell Park provides a comprehensive range of services to help you cope with the emotional, financial and day-to-day concerns related to your illness. When you walk through the doors of Roswell Park, rest assured that youll find the care and support you need - before, during and after your cancer treatment.
LUMOXITI™ (moxetumomab pasudotox-tdfk) is approved for treatment of hairy cell leukemia (HCL) in adults. Talk to your doctor and find out more about LUMOXITI and if it is right for you.
Lookchem Provide Cas No.60129-59-1 Basic information: Properties,Safety Data,Sds and Other Datebase. We also Provide Trading Suppliers & Manufacture for 60129-59-1 7-DEAZA-2-DEOXYADENOSINE.
This modification is available as part of a custom oligonucleotide configuration. Please use OLIGObuilder™ to generate pricing and order or contact us to speak with a customer service representative. ...
... cladribine - clarithromycin - clear cell adenocarcinoma - clear-cell sarcoma - clear cell sarcoma of the kidney - clinical ...
... cladribine MeSH D13.570.583.138.325 - deoxyadenosines MeSH D13.570.583.138.325.075 - cladribine MeSH D13.570.583.138.325.105 - ... cladribine MeSH D13.570.230.229.105 - dideoxyadenosine MeSH D13.570.230.229.650 - puromycin aminonucleoside MeSH D13.570. ... cladribine MeSH D13.570.800.096.500 - isopentenyladenosine MeSH D13.570.800.096.630 - phenylisopropyladenosine MeSH D13.570. ...
Cladribine is taken up by cells via a transporter. Once inside a cell cladribine is activated mostly in lymphocytes, when it is ... This is probably due to the fact cladribine more selectively targets B cells. Unlike alemtuzumab, cladribine is not associated ... Cladribine approved in Europe, Press Release *^ a b Giovannoni, G; Soelberg Sorensen, P; Cook, S; Rammohan, K; Rieckmann, P; ... cladribine is considered to be a highly effective immune reconstitution therapy in MS. Similar to alemtuzumab, cladribine is ...
Cladribine: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Do not take cladribine if you are pregnant or plan to become pregnant. If you become pregnant while taking cladribine, stop ... Before taking cladribine,. *tell your doctor and pharmacist if you are allergic to cladribine, any other medications, or any of ... Cladribine is generally used in patients who have already tried another treatment for MS. Cladribine in a class of medications ...
Cladribine Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Cladribine is used to treat hairy cell leukemia (cancer of a certain type of white blood cell). Cladribine is in a class of ... Cladribine may cause severe nerve damage. Nerve damage may occur more than one month after cladribine injection is given. If ... Before receiving cladribine,. *tell your doctor and pharmacist if you are allergic to cladribine, any other medications, or any ...
Cladribine: mechanisms and mysteries in multiple sclerosis.. Jacobs BM1, Ammoscato F2, Giovannoni G2,3, Baker D2, Schmierer K2, ... Cladribine is a safe and effective form of induction therapy for relapsing MS. Its mechanism of benefit is not fully understood ... The hypothesis that cladribines action of benefit is to deplete memory B cells is important: if correct, it implies that ... Clinical trial data argue strongly that cladribine is a safe and effective therapy for relapsing MS and that it may also be ...
A Moderate Drug Interaction exists between cladribine and clofarabine. View detailed information regarding this drug ... Using cladribine together with clofarabine may increase the risk of serious infections. Talk to your doctor if you have any ...
Detailed drug Information for cladribine Intravenous. Includes common brand names, drug descriptions, warnings, side effects ... Cladribine (Intravenous). Generic Name: cladribine (KLAD-ri-been). Intravenous route(Solution) Cladribine injection should be ... Infection-Cladribine may decrease your bodys ability to fight infection. Proper use of cladribine. Cladribine may cause mild ... Uses for cladribine. Cladribine belongs to the group of medicines called antimetabolites. It is used to treat hairy cell ...
Cladribine is usually given after other treatments have failed. Cladribine may also be used for purposes not listed in this ... Cladribine is used to treat relapsing multiple sclerosis (MS) in adults. This medicine will not cure MS, it will only decrease ... What is the most important information I should know about cladribine?. Do not take cladribine if you are pregnant. Both men ... What other drugs will affect cladribine?. If you take any other medicines by mouth, take your cladribine dose 3 hours before or ...
Has anyone heard of this ms drug "Cladribine"? It is an oral therapy, particularly one that has no short term side effects. It ... HealingWell.com Forum , Diseases & Conditions , Multiple Sclerosis , Cladribine Select A Location. ****** Top of the Forum ... is suggested that it is easy to use and that oral Cladribine, will have a major impact on the treatment of MS. ...
About Cladribine Tablets Cladribine Tablets is an oral small molecule prodrug that selectively and periodically targets ... Efficacy of Cladribine Tablets as Add-On to IFN-beta Therapy in Patients with Active Relapsing MS: Final Results from the Phase ... Cladribine Tablets is currently under clinical investigation and not approved for any use in the United States, Canada and ... We believe that Cladribine Tablets, if approved, would have a first-of-its-kind dosing regimen and serve as an important ...
... cladribine) is a disease modifying drug treatment for relapsing remitting multiple sclerosis. Read more about Mavenclad in this ... Other name: cladribine. Mavenclad is a disease modifying drug for very active relapsing remitting MS. You take Mavenclad as a ... Cladribine tablets for treating relapsing - remitting multiple sclerosis [TA493]. NICE Technology Appraisal Guidance 493 Full ... A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.. New England Journal of Medicine 2010;362(5): ...
The CLARITY (CLAdRIbine Tablets Treating MS OrallY) study: a two-year Phase III placebo-controlled study designed to evaluate ... Infections Cladribine can reduce the bodys immune defence and may increase the likelihood of infections. HIV infection, active ... Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first ... MAVENCLAD® (cladribine tablets) is approved in the European Union for the treatment of highly active relapsing multiple ...
Cladribine, unlike many other drugs, is toxic to both dividing and indolent lymphoid malignancies. Cladribine is a prodrug and ... 5-Nucleotidase (5-NT) dephosphorylates cladribine-MP and the accumulation of cladribine-TP depends on the ratio of dCK and 5 ... The cytotoxicity mainly depends on the accumulation of cladribine-triphosphates (TP) after phosphorylation of cladribine-MP by ... Finally, cladribine resistance may be a consequence of a defective induction of apoptosis. In spite of the fact that more than ...
... Thursday, November 9, 2017 General News ... The ONWARD (Oral Cladribine Added ON To Interferon beta-1a in Patients With Active Relapsing Disease) study: a Phase II placebo ... About MAVENCLAD In August 2017, the European Commission (EC) granted marketing authorization for MAVENCLAD (Cladribine Tablets ... The CLARITY (Cladribine Tablets Treating MS Orally) study: a two-year Phase III placebo-controlled study designed to evaluate ...
Cladribine. Hello I wanted to comment on cladribine. I had my first infusion September of 2016. In March 2017 I starting ... Sorry to hear you have had such a tough time on Cladribine. I started Cladribine last August/September so am due to have my ... I took cladribine as infusions for 5 days and then repeated dose in 1 month after. I am not certain of the dose I would have to ... If I wasnt on cladribine maybe the flare would have been catastrophic but at the same rate why did I have a flare up in the ...
Mavenclad (Cladribine Tablets) Receives First Approval in Latin America. Darmstadt, Germany (ots/PRNewswire) - Not intended for ... Efficacy of cladribine tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post-hoc ... Mavenclad (Cladribine Tablets) Data in Multiple Sclerosis Journal Show an Even Greater Treatment Effect in Patients With Highly ... Cladribine can reduce the bodys immune defence and may increase the likelihood of infections. HIV infection, active ...
SmartMed Technologies today announced that it is researching and testing cladribine as a potential treatment for patients who ... SmartMed Technologies today announced that it is researching and testing cladribine as a potential treatment for patients who ... Cladribine tablets could be the answer as a new treatment paradigm for relapsing multiple sclerosis and we look forward to ... Online PR News - 28-August-2020 - YEONGDEUNGPO-GU - SmartMed Technologies Medical team have researched cladribine over the ...
This database and website are updated and enhanced by Pesticide Action Network North America (PANNA). The project is made possible by our Sponsors and by PANNA general funds. We need your support to maintain and improve this system. Please support the database and website - donate to PANNA ...
... additional treatment with Cladribine Tablets beyond the 2-year CLARITY regimen. Patients who received Cladribine Tablets 3.5 mg ... The ONWARD (Oral Cladribine Added ON To Interferon beta-1a in Patients With Active Relapsing Disease) study: a Phase II placebo ... The CLARITY (Cladribine Tablets Treating MS Orally) study: a two-year Phase III placebo-controlled study designed to evaluate ... MAVENCLAD® (cladribine tablets) is approved in the European Union for the treatment of highly active relapsing multiple ...
Merck KGaA today said that it is now dumping cladribine after it had a chance to probe U.S. ... The failure of cladribine-U.S. regulators formally rejected the drug in March--is a black eye for Merck KGaA, which decided to ... The decision to pull the plug on cladribine also is good news for Biogen Idec, which has a closely watched program underway for ... "While this is not good news it was widely expected that the company would no longer seek global approval for cladribine ...
Investigators have discovered that clofarabine and cladribine may be used as a targeted therapy in diseases where CD99 plays a ... "Cladribine is already being used in treating an autoimmune disease," explained Dr. Ã ren. "Our findings can explain how ... "First, clofarabine and cladribine can be used as a targeted therapy for additional malignancies where CD99 plays a critical ... They report in Oncogene that both the drug clofarabine and cladribine, which is used to treat hairy cell leukemia, B-cell ...
... cladribine) tablets, which was approved by the U.S. Food and Drug Administration (FDA) on March 29, 2019. Express Scripts has ... About MAVENCLAD® (cladribine) Tablets (10 mg). MAVENCLAD, approved by the U.S. Food and Drug Administration (FDA) on March 29, ... The mechanism by which cladribine exerts its therapeutic effects in patients with multiple sclerosis has not been fully ... Because cladribine is cytotoxic, special handling and disposal instructions should be followed. ...
How is cladribine typically given (administered)? Cladribine is given intravenously (into a vein) as a continous infusion over ... What is the mechanism of action? Cladribine belongs to a group of drugs called antimetabolites. Cladribine produces its anti- ... For which conditions is this drug approved? Cladribine is FDA approved for the treatment of hairy cell leukemia and chronic ... Generic Name: Cladribine (KLAD-rah-been), 2CdA, 2-Chlorodeoxyadenosine. Trade Name: Leustatin® ...
Cladribine injection for infusion. What is this medicine?. CLADRIBINE (KLA dri been) is a chemotherapy drug. This medicine ... an unusual or allergic reaction to cladribine, benzyl alcohol, other medicines, foods, dyes, or preservatives ...
Cladribine with immediate Rituximab. Drug: Cladribine Cladribine 0.15 mg/Kg/day by 2-hour i.v. infusion days 1-5. The infusion ... Non-randomized group receving Cladribine with immediate Rituximab. Drug: Cladribine Cladribine 0.15 mg/Kg/day by 2-hour i.v. ... Drug: Cladribine Cladribine 0.15 mg/Kg/day by 2-hour i.v. infusion days 1-5. The infusion time may be changed to 1 hour at the ... To compare cladribine plus rituximab vs cladribine alone in terms of 1) initial MRD-free survival and disease-free survival, ...
Patients with HCLv with 0 to 1 prior courses of cladribine received cladribine 0.15 mg/kg for days 1 to 5, with eight weekly ... Although cladribine alone lacks effectiveness for early or relapsed HCLv, cladribine with immediate rituximab achieves CRs ... Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia.. Kreitman RJ1, Wilson W, ... By 6 months, 9 (90%) of 10 patients achieved CR, compared with 3 (8%) of 39 reported cases treated with cladribine alone (P , ...
Cladribine Injection For Intravenous Infusion Only), drug imprint information, side effects for the patient. ... What is cladribine (Cladribine Novaplus, Leustatin)?. *What are the possible side effects of cladribine (Cladribine Novaplus, ... How is cladribine given (Cladribine Novaplus, Leustatin)?. Cladribine is injected into a vein through an IV. You will receive ... What is cladribine (Cladribine Novaplus, Leustatin)?. Cladribine is a cancer medication that interferes with the growth and ...
Cladribine is used to treat certain type of blood cancer in which the bone marrow produces too many white blood cells, ... as Cladribine may not be suitable for you. Do not take this medicine if you are pregnant or planning to have a baby soon. If ... Do not take Cladribine with medicines that affect the production of blood cells in the bone marrow e.g. dipyrone. Inform your ... Use Cladribine exactly as directed by your doctor or according to the instructions on the label. Do not use more or less than ...
Cladribine is used to treat a type of blood cancer known as hairy cell leukemia. Cladribine fights cancer by preventing the ... Do not use cladribine if you are allergic to cladribine or any ingredients of the medication. ... Nerve damage: High doses of cladribine, and cladribine used with other treatments for cancer have been associated with damage ... The recommended dose of cladribine varies according to body weight. The medication is usually given at a dose of 0.09 mg per kg ...
Professor Ralf Gold offers unique insight into the recent EU approval of Cladribine, a treatment for active relapsing multiple ... Expert Opinion: Recent Approval of Cladribine in EU. Be part of the knowledge.™. *Log In ... Professor Ralf Gold offers unique insight into the recent EU approval of Cladribine, a treatment for active relapsing multiple ... Expert insight into the recent approval of Cladribine for active relapsing multiple sclerosis. ...
Cladribine prescription and dosage sizes information for physicians and healthcare professionals. Pharmacology, adverse ... Indications for Cladribine:. Active hairy cell leukemia.. Adult:. Give by continuous IV infusion for 7 consecutive days. 0.09mg ...
  • Cladribine , sold under the brand name Leustatin and Mavenclad among others, is a medication used to treat hairy cell leukemia (HCL, leukemic reticuloendotheliosis), B-cell chronic lymphocytic leukemia and Relapsing-remitting Multiple Sclerosis (RRMS) . (wikipedia.org)
  • Merck, a leading science and technology company, today announced that the European Commission (EC) has granted marketing authorization for MAVENCLAD® 10mg (Cladribine Tablets) for the treatment of highly active relapsing multiple sclerosis* (RMS)[1] in the 28 countries of the European Union (EU) in addition to Norway, Liechtenstein and Iceland. (presseportal.de)
  • Merck, a leading science and technology company, today announced that the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom (UK) has issued a final appraisal determination (FAD) recommending Cladribine Tablets (MAVENCLAD ) as an option for treating highly active multiple sclerosis * in adults. (medindia.net)
  • The CLARITY (Cladribine Tablets Treating MS Orally) study: a two-year Phase III placebo-controlled study designed to evaluate the efficacy and safety of MAVENCLAD as a monotherapy in patients with RRMS. (medindia.net)
  • Merck, a leading science and technology company, today announced the Multiple Sclerosis Journal publication of data outlining the effects of MAVENCLAD® (cladribine tablets) treatment on two subgroups of patients with highly active relapsing multiple sclerosis (MS)[1]. (presseportal.de)
  • MAVENCLAD® (cladribine tablets) is a short-course oral therapy that selectively and periodically targets lymphocytes thought to be integral to the pathological process of multiple sclerosis (MS). The clinical development program of Cladribine in MS comprises more than 10,000 patient years of data with over 2,700 patients included in the clinical trial program, and more than 10 years of observation in some patients. (presseportal.de)
  • MAVENCLAD® (cladribine tablets) is indicated for the treatment of adult patients with highly active relapsing multiple sclerosis (RMS) as defined by clinical or imaging features. (presseportal.de)
  • The trial, an extension of the Phase III CLARITY study, demonstrated that treatment of patients with relapsing remitting multiple sclerosis (MS) with MAVENCLAD ® (Cladribine Tablets) for two years, followed by two years of treatment with placebo, had clinical benefits similar to those seen with four years of treatment with MAVENCLAD ® , with a low risk of severe lymphopenia. (prnewswire.com)
  • MAVENCLAD® (Cladribine) Tablets Now Covered by Express Sc. (pharmiweb.com)
  • ROCKLAND, Mass., April 8, 2019 /PRNewswire/ -- EMD Serono, Inc. today announced that Express Scripts is covering on its formulary the oral multiple sclerosis (MS) therapy, MAVENCLAD ® (cladribine) tablets, which was approved by the U.S. Food and Drug Administration (FDA) on March 29, 2019. (pharmiweb.com)
  • About MAVENCLAD(®) (cladribine) Tablets (10 mg)MAVENCLAD, approved by the U.S. Food and Drug Administration (FDA) on March 29(th), 2019, is the first short-course oral therapy for the treatment of relapsing forms of multiple sclerosis (RMS). (europapress.es)
  • Hey I just got an email ad for Mavenclad (cladribine) and its apparently approved, but my doctor friend says never take a new treatment in the first. (thisisms.com)
  • Mavenclad (cladribine) approved for use by the NHS in. (thisisms.com)
  • The European Commission has approved Mavenclad, more commonly known as cladribine, for the treatment of highly active relapsing remitting multiple. (thisisms.com)
  • NHS England and Merck have reached an agreement that people eligible for treatment can access Mavenclad (cladribine) immediately. (mstrust.org.uk)
  • Mavenclad (cladribine) has been approved as a treatment for people with highly active relapsing MS on the NHS in England and Wales. (mstrust.org.uk)
  • Cladribine (brand name: Mavenclad ® ) is manufactured by Merck Serono. (multiplesclerosis.net)
  • 1. Cladribine (Mavenclad) for MS approved in Europe, Medscape. (multiplesclerosis.net)
  • Available at https://www.emdgroup.com/en/news/mavenclad-25-08-2017.html. (multiplesclerosis.net)
  • Available at https://merckneurology.co.uk/wp-content/uploads/2017/07/Mavenclad-Cladribine-PI.pdf. (multiplesclerosis.net)
  • What is Mavenclad (cladribine) for? (thesocialmedwork.com)
  • Mavenclad (cladribine) is a an oral nucleoside analog of deoxyadenosine indicated for the treatment people with relapsing forms of multiple sclerosis. (thesocialmedwork.com)
  • How does Mavenclad (cladribine) work? (thesocialmedwork.com)
  • The active substance in Mavenclad, cladribine, is a nucleoside analog of deoxyadenosine, meaning that it has a similar chemical structure to one of the substances needed to make up the DNA (purine). (thesocialmedwork.com)
  • Where has Mavenclad (cladribine) been approved? (thesocialmedwork.com)
  • How is Mavenclad (cladribine) taken? (thesocialmedwork.com)
  • Are there any known adverse reactions or side effects of Mavenclad (cladribine)? (thesocialmedwork.com)
  • ROCKLAND, Mass., March 29, 2019 (PRNewswire) - EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved MAVENCLAD® (cladribine) tablets for the treatment of adults with relapsing-remitting disease (RRMS) and active secondary progressive disease (SPMS). (cando-ms.org)
  • MAVENCLAD(R) (cladribine tablets) is approved in the European Union for the treatment of highly active relapsing multiple sclerosis* (RMS). (ufirms.ru)
  • Two short courses of oral cladribine (Mavenclad®, Merck KGaA ) over a period of two years can sustain the No Evidence of Disease Activity-3 (NEDA-3) status in certain relapsing-remitting multiple sclerosis (RRMS) patients for up to three additional years without further treatment, a new analysis presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2018 suggests. (medi-paper.com)
  • what I meant was that I don't get it why the norwegian hospitals by Mavenclad (cladribine tablets) for millions of NOKs, when cladribine is available in liquid form. (multiple-sclerosis-research.org)
  • Cladribine: mechanisms and mysteries in multiple sclerosis. (nih.gov)
  • The aims of this manuscript were to review the evidence for the efficacy and safety of cladribine in multiple sclerosis (MS) and to review the molecular and cellular mechanisms by which cladribine acts as a disease-modifying therapy in MS. (nih.gov)
  • Merck, a leading science and technology company, today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) of the investigational product Cladribine Tablets for the treatment of relapsing-remitting multiple sclerosis (MS). (prnewswire.com)
  • Our submission of the Marketing Authorization Application for Cladribine Tablets demonstrates Merck's continued commitment to fighting the devastating disease of multiple sclerosis,' said Luciano Rossetti , Head of Global R&D for the Biopharma business of Merck. (prnewswire.com)
  • A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis. (prnewswire.com)
  • Safety and Efficacy of Oral Cladribine in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the 96 Week Phase IIIb Extension Trial to the CLARITY Study (P07.119). (prnewswire.com)
  • Effect of Oral Cladribine on Time to Conversion to Clinically Definite Multiple Sclerosis in Patients with a First Demyelinating Event (ORACLE MS): A Phase 3 Randomised Trial. (prnewswire.com)
  • A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD). (prnewswire.com)
  • Current and Emerging Therapies for the Treatment of Multiple Sclerosis: Focus on Cladribine. (prnewswire.com)
  • SmartMed Technologies today announced that it is researching and testing cladribine as a potential treatment for patients who relapse from Multiple Sclerosis. (onlineprnews.com)
  • Online PR News - 28-August-2020 - YEONGDEUNGPO-GU - SmartMed Technologies' Medical team have researched cladribine over the last few years as a short-course of treatment and oral therapy which is thought to selectively target lymphocytes, which could be integral to the pathological process of relapsing multiple sclerosis. (onlineprnews.com)
  • Cladribine tablets could be the answer as a new treatment paradigm for relapsing multiple sclerosis and we look forward to carrying out more tests to come to a final conclusion. (onlineprnews.com)
  • In CLARITY, patients with active relapsing-remitting multiple sclerosis were randomized to placebo or 1 of 2 cumulative doses of Cladribine Tablets (3.5 or 5.25 mg/kg body weight) for 2 years. (prnewswire.com)
  • Once considered a leader in the heated race to develop the first oral treatment for multiple sclerosis, Merck KGaA today said that it is now dumping cladribine after it had a chance to probe U.S. regulators' safety issues on the drug. (fiercebiotech.com)
  • They report in Oncogene that both the drug clofarabine and cladribine, which is used to treat hairy cell leukemia, B-cell chronic lymphocytic leukemia, and multiple sclerosis, may help effectively target Ewing sarcoma cells as well. (cancernetwork.com)
  • Expert insight into the recent approval of Cladribine for active relapsing multiple sclerosis. (reachmd.com)
  • Professor Ralf Gold offers unique insight into the recent EU approval of Cladribine, a treatment for active relapsing multiple sclerosis. (reachmd.com)
  • The mechanism by which cladribine exerts its therapeutic effects in patients with multiple sclerosis has not been fully elucidated but is thought to involve cytotoxic effects on B and T lymphocytes through impairment of DNA synthesis, resulting in depletion of lymphocytes. (europapress.es)
  • Cladribine is a purine nucleoside analogue that interferes with the behavior and the proliferation of certain white blood cells, particularly lymphocytes, which are involved in the pathological process of multiple sclerosis. (thisisms.com)
  • Through its differentiated mechanism of action, oral cladribine may offer an alternative option to patients with multiple sclerosis. (thisisms.com)
  • OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and safety of cladribine, a purine analog undergoing Phase III trials for approval of its use in the treatment of multiple sclerosis (MS). DATA SOURCES: A MEDLINE search (1966-September 2006) was conducted using the key words cladribine and multiple sclerosis. (thisisms.com)
  • The product information for cladribine for the multiple sclerosis indication already includes a warning about the risk of PML. (www.gov.uk)
  • Merck, a leading science and technology company, today announced that MAVENCLADR (cladribine tablets) has been approved for the treatment of highly active relapsing remitting multiple sclerosis* (RRMS)[1] in Switzerland. (padovanews.it)
  • Merck KGaA, Darmstadt, Germany today announced the presentation of new data for cladribine tablets at the 34th Congress of the European Committee for Treatment and Research In Multiple Sclerosis (ECTRIMS). (emdgroup.com)
  • Updated safety analysis of Cladribine Tablets in the treatment of patients with multiple sclerosis. (emdgroup.com)
  • Sustained efficacy in relapsing remitting multiple sclerosis following switch to placebo treatment from Cladribine Tablets in patients with high disease activity at baseline. (emdgroup.com)
  • Cladribine Multiple Sclerosis is a frequently mentioned investigation in view of the reason that it is applicable to Multiple Sclerosis Age, Multiple Sclerosis Age Of Onset, and Multiple Sclerosis And Anesthesia. (multiple-sclerosis-cures.com)
  • Could this be a concern: Cladribine Multiple Sclerosis? (multiple-sclerosis-cures.com)
  • The post hoc analysis showed that Cladribine Tablets reduced the annualized rate of brain volume loss - also known as brain atrophy - compared with placebo in patients with relapsing remitting multiple sclerosis (RRMS). (emdgroup.com)
  • CLARITY: CLAdRIbine Tablets treating multiple sclerosis orallY. (mavenclad.com)
  • Multiple Sclerosis Research: PML warning on Cladribine by MHRA. (blogspot.com)
  • In 2009, German drug maker Merck KGaA expected to seek United States and European Regulatory (Food and Drug Administration U.S.A) approval for the first oral medication cladribine for the treatment of multiple sclerosis (MS): Preventing sporadic symptoms of multiple sclerosis a neurological disease. (yuptab.com)
  • 6 Cladribine combats the genetically abnormal white bloods cells (particularly lymphocytes) involved in the autoimmune disease attributed to multiple sclerosis. (yuptab.com)
  • Efficacy and Safety of Intravenous Cladribine in Patients with Rapidly Evolving or Early Secondary Progressive Multiple Sclerosis . (multiple-sclerosis-research.org)
  • Four patients who were already diagnosed with rapidly evolving or early secondary progressive multiple sclerosis (SPMS) were induced with cladribine. (multiple-sclerosis-research.org)
  • It is important to note that approximately 40% of oral cladribine is bioavailable orally. (wikipedia.org)
  • It is suggested that it is easy to use and that oral Cladribine, will have a major impact on the treatment of MS. (healingwell.com)
  • Serono announced today that oral cladribine has been designated a Fast Track product by the US Food and Drug Administration (FDA). (thisisms.com)
  • We are very pleased that oral cladribine has been designated a Fast Track product," said Ernesto Bertarelli, CEO of Serono. (thisisms.com)
  • Under Fast Track designation oral cladribine is eligible for Priority Review and FDA may consider for review portions of the marketing application before the New Drug Application (NDA) is completed. (thisisms.com)
  • To date, there is one ongoing study examining the role of oral cladribine in the treatment of relapsing-remitting MS. The incidence of adverse effects with cladribine has been significantly greater than with placebo, with the most common being myelosuppression. (thisisms.com)
  • This sustained effect on lymphocytes is advantageous for patients with MS. CLARITY (CLAdRIbine Tablets Treating MS OrallY), a Phase III trial, has demonstrated that short-term oral cladribine decreases relapse rates and risk of disability progression in comparison with placebo. (pubmedcentralcanada.ca)
  • An ongoing study is evaluating the efficacy and safety of the combination of oral cladribine and IFN-β products. (pubmedcentralcanada.ca)
  • A further ongoing study is examining the use of oral cladribine in clinically isolated syndrome and time to conversion to MS. Although the results of CLARITY are promising, the exact role of oral cladribine may be better defined with the completion of ongoing studies. (pubmedcentralcanada.ca)
  • These trials were terminated when the manufacturers decided to can the development of oral cladribine. (cashnetusa.top)
  • Severe lymphopenia (grade 3/4) occurred in about 85% of our cohort of people treated with alemtuzumab, verses 1.5% treated with generic cladribine in our does-adjusted study and 6% in the first year of the oral cladribine CLARITY study. (cashnetusa.top)
  • When we explore the safety data of oral cladribine, from both the trial programme and post-marketing surveillance, we really don't see a significant viral infection signal in cladribine-treated subjects. (multiple-sclerosis-research.org)
  • The study below show that oral cladribine has an impact on accelerated brain atrophy in pwMS. (blogspot.ie)
  • Please note we are proposing that redoing of oral cladribine only happens if your lymphocyte count is above 800. (blogspot.ie)
  • The CLARITY study was a 2-year, Phase III, randomised controlled trial that had demonstrated significant efficacy with oral cladribine vs placebo. (medi-paper.com)
  • After the completion of CLARITY, patients in the two dosing arms of oral cladribine were re-randomised to cladribine or placebo in the CLARITY Extension study. (medi-paper.com)
  • Of the 284 CLARITY-patients who received a cumulative dose oral cladribine of 3.5 mg/kg over 2 years, 98 were re-randomised to placebo and 186 were re-randomised to continue cladribine at the initial dosing in CLARITY Extension. (medi-paper.com)
  • The investigators concluded that for both groups of patients receiving placebo or cladribine after a 2-year course of oral cladribine 3.5 mg/kg, they "experienced sustained benefits for NEDA-3, or its components" in the CLARITY Extension. (medi-paper.com)
  • What is cladribine (Cladribine Novaplus, Leustatin)? (rxlist.com)
  • What are the possible side effects of cladribine (Cladribine Novaplus, Leustatin)? (rxlist.com)
  • What is the most important information I should know about cladribine (Cladribine Novaplus, Leustatin)? (rxlist.com)
  • What should I discuss with my healthcare provider before receiving cladribine (Cladribine Novaplus, Leustatin)? (rxlist.com)
  • How is cladribine given (Cladribine Novaplus, Leustatin)? (rxlist.com)
  • Despite initial very high response rates with cladribine (Leustatin), many patients ultimately relapse. (cancernetwork.com)
  • Cladribine is available as a solution for injection generically and under the trade name Leustatin. (wikimd.org)
  • Cladribine (Leustatin) only comes as a generic medication and is used for treating hairy cell leukemia, a form of blood cancer. (healthery.com)
  • Patients in complete remission (CR) to cladribine have minimal residual disease (MRD) by immunohistochemistry of the bone marrow biopsy (BMBx IHC), a risk for early relapse. (clinicaltrials.gov)
  • To compare cladribine plus rituximab vs cladribine alone in terms of 1) initial MRD-free survival and disease-free survival, and 2) response to delayed rituximab for relapse, to determine if early rituximab compromises later response. (clinicaltrials.gov)
  • Rituximab 375 mg/m2/week times 8 weeks, randomized half to begin day 1, then repeat for all patients with blood-MRD relapse at least 6 months after cladribine. (clinicaltrials.gov)
  • These findings reinforce and expand on the consistent and positive effect of Cladribine Tablets in improving clinically relevant outcomes, such as reducing relapse rate and disability, and further our resolve to make this investigational therapy available for patients living with RRMS," said Steven Hildemann, MD, PhD, Global Chief Medical Officer and Head of Global Medical Affairs and Safety, Merck KGaA, Darmstadt, Germany. (emdgroup.com)
  • In addition, follow-up analysis of CLARITY and CLARITY Extension found that up to 90% of those who received cladribine were free of new lesions on MRI and up to 81% remained relapse-free after 4 years. (multiplesclerosis.net)
  • Patients treated with cladribine tablets 3.5 mg/kg/IFN-β were 63% less likely to have a qualifying relapse than placebo/IFN-β recipients, and cladribine tablets 3.5 mg/kg/IFN-β reduced most MRI measures of disease activity. (cashnetusa.top)
  • The annualised relapse rate was 0.12 on cladribine/beta interferon verses 0.32 with beta interferon alone. (cashnetusa.top)
  • So the cladribine relapse rate was similar to that observed in the CLARITY study. (cashnetusa.top)
  • The mean relapse rate in the two years before patients were given cladribine was 1.25. (multiple-sclerosis-research.org)
  • Conclusion P arenteral cladribine reduced the relapse rate from 1.25 to 0.42 , which was statistically significant (p-value = 0.002). (multiple-sclerosis-research.org)
  • Since 2017, cladribine is approved as an oral formulation (10 mg tablet) for the treatment of RRMS in Europe, UAE, Argentina, Chile, Canada and Australia. (wikipedia.org)
  • I ended up doing another round of cladribine in October 2017. (shift.ms)
  • As of March 2017, 3 confirmed reports of PML (including at least 1 fatal case) have been reported in patients worldwide taking cladribine for various haematological conditions. (www.gov.uk)
  • As part of this analysis, an overview of the post-approval safety data from EU approval on August 2017 to July 2018 also showed no new safety or tolerability signals for cladribine tablets. (emdgroup.com)
  • 2017-02-09 Cladribine Tablets Significantly Reduced Brain Atrophy in Patients with. (emdgroup.com)
  • In August 2017, cladribine was approved for the treatment of people with highly active relapsing forms of MS in the European Union, Norway, Liechtenstein, and Iceland. (multiplesclerosis.net)
  • Merck announced the presentation of new analyses of efficacy and safety data for investigational Cladribine Tablets in poster presentations at the Annual Meeting of the American Academy of Neurology (AAN), that took place April 22 - 28, 2017, in Boston, Massachusetts. (news-medical.net)
  • Cladribine injection must be given in a hospital or medical facility under the supervision of a doctor who is experienced in giving chemotherapy medications for cancer. (medlineplus.gov)
  • Cladribine is FDA approved for the treatment of hairy cell leukemia and chronic lymphocytic leukemia that does not respond to other chemotherapy agents referred to as alkylating agents. (unm.edu)
  • CLADRIBINE (KLA dri been) is a chemotherapy drug. (ahealthyme.com)
  • Drugs used in chemotherapy, such as venetoclax , cladribine, and low dose cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. (clinicaltrials.gov)
  • Because cladribine, ara-C, and mitoxantrone chemotherapy medications work best when cells are dividing, GCSF causes more AML leukemia cells to die from chemotherapy. (chemoexperts.com)
  • Cladribine, known chemically as (2-Chloro-2′-deoxyadenosine), is a purine analog chemotherapy used for hairy cell leukemia and other B-cell lymphomas. (multiple-sclerosis-research.org)
  • adverse event rates were similar in patients who received Cladribine Tablets in CLARITY followed by placebo in CLARITY Extension, and those who received Cladribine Tablets in both studies. (prnewswire.com)
  • In CLARITY Extension, patients were administered placebo or a cumulative dose of Cladribine Tablets 3.5 mg/kg body weight. (prnewswire.com)
  • In the patient group receiving placebo in CLARITY Extension following Cladribine Tablets 3.5 mg/kg in CLARITY, 3.1% of patients discontinued because of AEs. (prnewswire.com)
  • In a phase III study, cladribine reduced relapses by 58% compared to placebo and also reduced the risk of disability progression. (mstrust.org.uk)
  • In the two-year CLARITY study, the most commonly reported adverse event (AE) in patients treated with cladribine tablets was lymphopenia (26.7% with cladribine tablets and 1.8% for placebo). (padovanews.it)
  • The incidence of infections was 48.3% with cladribine tablets and 42.5% with placebo, with 99.1% and 99.0% respectively rated mild-to-moderate by investigators. (padovanews.it)
  • Adjusted adverse events incidences per 100 patient-years (Adj-AE per 100PY) for those experiencing ≥1 serious TEAE were 3.88 for cladribine tablets and 3.24 for placebo in the two-year update, versus 4.00 for cladribine tablets and 3.57 for placebo reported previously. (emdgroup.com)
  • P ost hoc analyses of CLARITY EXT show that following 20 days of treatment with cladribine tablets 3.5 mg/kg in Years 1 and 2 annual NEDA-3 status was sustained in patients treated with cladribine tablets 3.5 mg/kg or placebo up to the end of Year 4^2^.There is also an analysis of EDSS, and clinical and MRI outcomes in patients with high disease activity. (emdgroup.com)
  • With regards to MRI measures, the data showed that the number of cumulative new T1 Gd+ and active T2 lesions at Week 96 was reduced with cladribine tablets compared to placebo in both age groups 3 . (emdgroup.com)
  • The CLARITY study was a two-year (96-week), randomized, double-blind, placebo-controlled Phase III study of Cladribine Tablets in 1,326 people with RRMS. (emdgroup.com)
  • The mean percentage brain volume loss per year was significantly reduced in patients treated with Cladribine Tablets 3.5 mg/kg (-0.56%±0.68, p=0.010, n=336) and 5.25 mg/kg (-0.57%±0.72, p=0.019, n=351) compared with patients treated with placebo (-0.70%±0.79, n=338). (emdgroup.com)
  • Study participants were randomized to one of three different treatment groups consisting of two different dose regimens of Cladribine Tablets or matching placebo tablets (1:1:1 ratio). (emdgroup.com)
  • In the all-exposed cohort, the incidence of autoimmune diseases was slightly lower in the cladribine group (0.58 events per 100 patient-years) than in the placebo group (0.73 events per 100 patient-years). (mavenclad.com)
  • METHODS: A 96-week phase II study, randomizing patients treated with IFN-β to cladribine tablets 3.5 mg/kg/IFN-β or placebo/IFN-β. (cashnetusa.top)
  • Patients were to receive cladribine tablets 3.5 mg/kg/IFN-β or placebo/IFN-β in a 2:1 ratio (n = 172) with safety and exploratory efficacy outcomes being assessed. (cashnetusa.top)
  • CONCLUSIONS: In patients with active relapsing MS despite IFN-β treatment, cladribine tablets 3.5 mg/kg/IFN-β reduced relapses and MRI lesion activity over 96 weeks compared with placebo/IFN-β but led to an increased incidence of lymphopenia. (cashnetusa.top)
  • This is important because CD8+ T-cells are the cells responsible for fighting viral infections and explains, apart from a small risk of herpes zoster reactivation, why we didn't see an increase in viral infections compared to placebo in cladribine treated subjects in the phase 3 trial programme. (multiple-sclerosis-research.org)
  • In the Year 3 - 4 group, annual NEDA-3 was achieved in 46.3% of patients who were randomised to cladribine in CLARITY followed by placebo in the CLARITY Extension, vs 48.0% of whom were received cladribine in both studies. (medi-paper.com)
  • In the Year 4 - 5 group, annual NEDA-3 was achieved in 35.0% of patients receiving cladribine followed by placebo and 48.1% of patients receiving cladribine in both protocols, respectively. (medi-paper.com)
  • The most frequent AE in patients receiving Cladribine Tablets in the CLARITY Extension study was lymphopenia. (prnewswire.com)
  • Based on an integrated analysis of patients from the CLARITY, CLARITY EXT, and ORACLE-MS trials, including two additional years of data from the long-term PREMIERE Registry, the treatment emergent adverse event (TEAE) profile associated with cladribine tablets in patients with relapsing MS (RMS) was confirmed, with no new safety findings. (emdgroup.com)
  • The brain atrophy analysis evaluated the effect of Cladribine tablets on brain volume loss (BVL) over 2 years in RMS and the association of BVL with confirmed disability progression in 1,025 (77.3%) of the patients in CLARITY. (emdgroup.com)
  • Cladribine inhibts MS, as was shown in the CLARITY trials, but it was also indicated in other trials. (cashnetusa.top)
  • Serious neurological toxicity (including irreversible paraparesis and quadriparesis) has been reported in patients who received cladribine injection by continuous infusion at high doses (4 to 9 times the recommended dose for hairy cell leukemia). (drugs.com)
  • Only 4 HCL-specific trials are listed on Cancer.gov: a phase II trial of cladribine followed 4 weeks later by 8 weekly doses of rituximab, and phase I-II trials of recombinant immunotoxins targeting CD22 (BL22, HA22) and CD25 (LMB-2). (clinicaltrials.gov)
  • Patients with HCLv with 0 to 1 prior courses of cladribine received cladribine 0.15 mg/kg for days 1 to 5, with eight weekly doses of rituximab 375 mg/m(2) beginning day 1. (nih.gov)
  • In high doses, above what is recommended for hairy cell leukemia , cladribine has been reported to have acute neurologic toxicity. (wikimd.org)
  • Recently, some randomized studies have demonstrated improved outcomes with regimens containing high-dose cytarabine, cladribine, or escalated doses of anthracyclines during induction. (ehaweb.org)
  • Kidney damage has been reported in people receiving high doses of cladribine for the treatment of conditions other than hairy cell leukemia . (emedtv.com)
  • Nerve damage is mostly associated with high doses of cladribine, and is rare with normally recommended amounts. (emedtv.com)
  • Shortness of breath held and other adverse gi effects may anywhere be minimized by administering Cladribine with milk or food, or in 2 divided doses approximately 30 minutes apart, or by reducing your dosage. (pastande.org)
  • Because of the progression of the disease, treatment with standard doses of cladribine was initiated in June 1994 and repeated in August 1994. (meds.com)
  • This is a narrative review of the available clinical and preclinical data on the use of cladribine in MS. (nih.gov)
  • Clinical trial data argue strongly that cladribine is a safe and effective therapy for relapsing MS and that it may also be beneficial in progressive MS. The pharmacology of cladribine explains how it is selectively toxic towards lymphocytes. (nih.gov)
  • All available in vitro and clinical data on cladribine was undertaken. (diva-portal.org)
  • An oral treatment approach consisting of short and infrequent cycles may help lower the treatment burden for patients and based on our clinical research in recent years, we have gained more knowledge for the treatment course of cladribine and we hope to announce a breakthrough very soon," added Dr. Norman Hammond, Chief Medical Officer of SmartMed Technologies. (onlineprnews.com)
  • To determine if MRD levels and tumor markers (soluble CD25 and CD22) after cladribine and/or rituximab correlate with response and clinical endpoints. (clinicaltrials.gov)
  • The data presented at ECTRIMS 2018 build on the existing real-world and clinical evidence around the safety and efficacy of cladribine tablets and reaffirm the benefit-risk profile of the oral treatment which is taken for a maximum of 20 days over two years. (emdgroup.com)
  • Three of 1,976 (0.2%) cladribine-treated patients in the clinical program developed tuberculosis. (mavenclad.com)
  • In clinical research, Cladribine has been shown to reduce the frequency of MS relapses and to delay disease progression. (multiplesclerosis.net)
  • The most common side effects experienced by people taking cladribine in clinical trials were lymphopenia (a decrease in lymphocytes) and herpes zoster (shingles). (multiplesclerosis.net)
  • About 24% of cladribine-treated patients in the clinical trial program were followed for up to 8 years. (mavenclad.com)
  • Fatal cases of TB (1 case) and hepatitis (1 case) happened with cladribine during clinical studies. (mavenclad.com)
  • Cladribine may be included in the next list of assessments according to the National Institute of Health and Clinical Excellence (NICE). (yuptab.com)
  • 2020. https://www.drugguide.com/ddo/view/Davis-Drug-Guide/51158/all/cladribine. (drugguide.com)
  • Once inside a cell cladribine is activated mostly in lymphocytes, when it is triphosphorylated by the enzyme deoxyadenosine kinase (dCK). (wikipedia.org)
  • Cladribine is a safe and effective form of induction therapy for relapsing MS. Its mechanism of benefit is not fully understood but the most striking action is selective, long-lasting, depletion of B lymphocytes with a particular predilection for memory B cells. (nih.gov)
  • Cladribine is a disease modifying drug for people with relapsing remitting MS . It works by reducing the number of white blood cells, known as lymphocytes, which cause the nerve damage associated with MS. The drug is therefore able to slow down or stop the immune attack and reduce the damage to the brain and spinal cord. (mstrust.org.uk)
  • Cladribine is an antimetabolite, which works against lymphocytes (a type of white blood cell that plays a key role in the immune system's inflammatory response). (multiplesclerosis.net)
  • Cladribine disrupts the DNA of lymphocytes, leading to depletion of T-cells and B-cells (types of lymphocyte). (multiplesclerosis.net)
  • The active ingredient cladribine is approved in the EU, USA, and TGA, among others as an intravenous infusion for the treatment of certain leukemias (cancers affecting lymphocytes). (thesocialmedwork.com)
  • In the body, cladribine is taken up by cells such as lymphocytes and therein interferes with the production of new DNA. (thesocialmedwork.com)
  • I n another case (67 years old) reported 6 months after the last dose of cladribine had 160 CD4+ cells/mm3 and 360 CD8+ cells/mm3 but had been down to 100 lymphocytes cells/mm3). (blogspot.com)
  • Cladribine is already approved in the EU for the treatment of certain leukaemias (cancers affecting lymphocytes). (europa.eu)
  • On cladribine, T lymphocytes are in general depleted by about 40% and the vast majority of patients don't drop their counts below 500/mm3. (multiple-sclerosis-research.org)
  • Cladribine is one of the agents that enters the central nervous system and hence is likely to impact on lymphocytes within the target organ and hence may have delayed benefits that won't be seen in the initial 24 month window. (blogspot.ie)
  • The recommended dose of cladribine varies according to body weight. (pharmasave.com)
  • Determine the maximum tolerated dose of cladribine when administered after bryostatin 1 in patients with relapsed chronic lymphocytic leukemia. (knowcancer.com)
  • Apart from having a full blood count before your next dose of cladribine there is really no need for blood monitoring. (blogspot.ie)
  • To compare response and MRD after the 1st and 2nd courses of cladribine. (clinicaltrials.gov)
  • HCL with 0-1 prior courses of cladribine and treatment indicated. (clinicaltrials.gov)
  • range: 19-119 months),eight patients received two prior courses of cladribine, five patients receivedinterferon, and two patients had undergone splenectomy. (cancernetwork.com)
  • While this is not good news it was widely expected that the company would no longer seek global approval for cladribine following the negative FDA decision last fall. (fiercebiotech.com)
  • 3 The Food Drug Administration has granted Fast Track approval for cladribine: Expedite review and development of new drugs for serious or life-threatening conditions for unmet medical needs. (yuptab.com)
  • In comparison, in MS, cladribine is associated with a 6% rate of severe lymphocyte suppression (lymphopenia) (levels lower than 50% of normal). (wikipedia.org)
  • Since cladribine can induce myelosuppression and immunosuppression, as well as lymphopenia that can last several months, it is thought to be biologically plausible that it could increase the risk of PML. (www.gov.uk)
  • Lymphopenia was the most commonly reported adverse event (AE) in patients treated with Cladribine Tablets. (emdgroup.com)
  • Because of the risk of lymphopenia, a person's blood must be tested before receiving cladribine to ensure they have a normal amount of white blood cells. (multiplesclerosis.net)
  • CLASSIFICATION OF EVIDENCE:This study provides Class I evidence that for patients with active relapsing MS despite IFN-β treatment, cladribine tablets added to IFN-β reduced relapses and MRI lesion activity over 96 weeks and increased the incidence of lymphopenia. (cashnetusa.top)
  • 500 cells/microlitre) lymphopenia following 5mg/kg cladrine and beta interferon), this dose was discontinued but about 65% of people got severe lymphopenia following delivery of 3.5mg/kg cladribine and beta interferon, so much more than with cladribine alone. (cashnetusa.top)
  • 1 ) Cladribine can cause profound immunosuppression, lymphopenia, and increased susceptibility to opportunistic infections. (meds.com)
  • Furthermore, we showed that cladribine induced apoptosis by decreasing the expression of c-FLIP L and increasing the expression of DR4 and the cleaved form of caspase8. (omgcb.com)
  • Tell your doctor if you have ever had any unusual or allergic reaction to cladribine or any other medicines. (drugs.com)
  • The failure of cladribine-U.S. regulators formally rejected the drug in March--is a black eye for Merck KGaA, which decided to seek regulatory approval on the basis of a single late-stage trial. (fiercebiotech.com)
  • The data presented at ECTRIMS 2018 highlight our commitment to continuing to understand the extended benefit-risk profile of cladribine tablets," said Luciano Rossetti, Head of Global R&D for the biopharma business of Merck KGaA, Darmstadt, Germany. (emdgroup.com)
  • Before you receive cladribine, tell your doctor If you have liver or kidney disease or a bone marrow problem. (rxlist.com)
  • If you miss an appointment to receive cladribine, contact your doctor as soon as possible to reschedule your appointment. (pharmasave.com)
  • INDUCTION: Patients receive cladribine intravenously (IV) daily over 1-2 hours on days 1-5, cytarabine subcutaneously (SC) twice daily (BID) on days 1-10, and venetoclax orally (PO) daily on days 1-21. (clinicaltrials.gov)
  • Patients who achieve CR or CRi after cycle 1 of induction receive cladribine IV over 1-2 hours daily on days 1-3, cytarabine SC BID on days 1-10, and venetoclax PO once daily (QD) on days 1-21 of cycle 2. (clinicaltrials.gov)
  • Patients who received cladribine experienced up to a sixty percent reduction in the relapsing symptoms of MS (depending on the dosage 1). (yuptab.com)
  • Cladribine tablets had a greater effect on B cells than T cells, and no hyperpopulation of B cells was observed after treatment with cladribine tablets. (activemsers.org)
  • Cladribine is generally used in patients who have already tried another treatment for MS. Cladribine in a class of medications called purine antimetabolites. (medlineplus.gov)
  • Cladribine belongs to the group of medicines called antimetabolites. (drugs.com)
  • Cladribine belongs to the group of cancer-fighting medications known as antineoplastics , and specifically to the group of antineoplastics known as antimetabolites . (pharmasave.com)
  • Cladribine (klad' ri been) is a purine analogue (2-chlorodeoxyadeosine) that is used predominantly in the treatment of hairy cell leukemia . (wikimd.org)
  • In vitro studies demonstrate that cladribine also exerts immunomodulatory influences over innate and adaptive immunity. (nih.gov)
  • In vitro combination treatment with SAHA and cladribine dose-dependently exerts synergistic cytotoxic and apoptotic effects on leukaemic NK cells. (pcom.edu)
  • Our data suggest that MM patients with the features of MM1.S cells may particularly benefit from cladribine monotherapy, whereas cladribine in combination with STAT3 inhibitor exerts a broader therapeutic potential against MM. (biomedcentral.com)
  • Cladribine was well tolerated in the study, with the most common adverse effects being headache, nausea, upper respiratory tract infections, and lymphocytopenia. (pubmedcentralcanada.ca)
  • Results showed no new adverse events for cladribine tablets have been seen since the first approval in Europe last year. (emdgroup.com)
  • What are the most common adverse effects or side effects with cladribine? (multiplesclerosis.net)
  • Cladribine had some serious adverse effects. (cashnetusa.top)
  • However, cladribine's immune depletion and reconstitution, and adverse event profile are very different to alemtuzumab's and therefore cladribine should be considered on its own when weighing up the risks and benefits of treating highly-active MS during the COVID-19 pandemic. (multiple-sclerosis-research.org)
  • tell your doctor and pharmacist if you are allergic to cladribine, any other medications, or any of the ingredients in cladribine tablets. (medlineplus.gov)
  • Cladribine is in a class of medications known as purine analogs. (medlineplus.gov)
  • Many other medications may also interact with cladribine, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list. (medlineplus.gov)
  • You may receive other medications to help prevent certain side effects of cladribine. (rxlist.com)
  • Combining cladribine with biologic and immunologic medications that suppress the immune system could increase your risk for potentially serious side effects, including low blood cell counts and infections. (emedtv.com)
  • It is also important for your healthcare provider to know about any other medications, vitamins, or supplements you are taking to avoid potentially serious drug interactions with cladribine. (emedtv.com)
  • Kidney damage was more likely to occur when cladribine was used in combination with other medications that can cause kidney problems. (emedtv.com)
  • Like certain other anticancer medications, cladribine has been reported to cause a condition known as tumor lysis syndrome. (emedtv.com)
  • Cladribine is used for as a first and second-line treatment for symptomatic hairy cell leukemia and for B-cell chronic lymphocytic leukemia and is administered by intravenous or subcutaneous infusion. (wikipedia.org)
  • Cladribine is given intravenously (into a vein) as a continous infusion over multiple days. (unm.edu)
  • No dose-limiting toxicities were observed when beginning cladribine and rituximab on the same day, although most patients required short-term steroids to prevent and treat rituximab infusion reactions. (nih.gov)
  • Cladribine must be given slowly through an IV infusion, and you will receive it around the clock for 7 days in a row. (rxlist.com)
  • A cohort of seven male patients with biopsy proved multisystem (six cases) and multifocal (one case) Langerhans cell histiocytosis received cladribine at a dose of 5 mg/m(2) subcutaneously (five cases) or by two-hour intravenous infusion (two cases) over five consecutive days, every four weeks for a median of four courses (range 4-6). (muni.cz)
  • Cladribine is given as an intravenous (into the vein) injection. (pharmasave.com)
  • Cladribine is used to treat hairy cell leukemia (cancer of a certain type of white blood cell). (medlineplus.gov)
  • Hairy cell leukemia (HCL) is highly responsive to but not curable by cladribine (CdA). (clinicaltrials.gov)
  • Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia. (nih.gov)
  • Cladribine is used to treat hairy cell leukemia (a type of blood cancer). (rxlist.com)
  • Cladribine is used to treat certain type of blood cancer in which the bone marrow produces too many white blood cells, particularly hairy cell leukaemia. (mims.com)
  • This may be an effective treatment for hairy cell leukemia that has not responded to treatment with cladribine. (clinicaltrials.gov)
  • PURPOSE: This phase II trial is studying BL22 immunotoxin to see how well it works in treating patients previously treated with cladribine for hairy cell leukemia. (clinicaltrials.gov)
  • Determine the response rate in patients with cladribine-resistant hairy cell leukemia treated with BL22 immunotoxin. (clinicaltrials.gov)
  • Compare the acute hematotoxicity and infection rate with daily and weekly administration of cladribine in patients with hairy cell leukemia. (knowcancer.com)
  • Cladribine is a purine analogue and antineoplastic agent used primarily in the therapy of hairy cell leukemia . (wikimd.org)
  • Cladribine was found to have marked activity against hairy leukemia and was approved for this use in the United States in 1993. (wikimd.org)
  • Cladribine has been used off-label to treat low grade lymphomas and other hematologic malignancies, but its current formal indications are limited to therapy of active hairy cell leukemia . (wikimd.org)
  • Cladribine is a purine nucleoside analog used to treat B-cell chronic lymphocytic leukemia and hairy cell leukemia, also functions as an inhibitor of DNA synthesis to block the repair of the damaged DNA. (omgcb.com)
  • Cladribine or 2-chlorodeoxyadenosine (2-CDA) is a well-known purine nucleoside analog with particular activity against lymphoproliferative disorders, such as hairy cell leukemia (HCL). (biomedcentral.com)
  • If you become pregnant while taking cladribine, stop taking cladribine and call your doctor immediately. (medlineplus.gov)
  • Currently, interferon (IFN) products, including IFN β-1a administered intramuscularly or subcutaneously and IFN β-1b subcutaneously, glatiramer acetate, natalizumab, and mitoxantrone are approved disease-modifying therapies for the treatment of relapsing-remitting MS. Cladribine, also known as 2-chlorodeoxyadenosine, is a synthetic adenosine deaminase-resistant purine nucleoside analog that preferentially depletes lymphocyte subpopulations. (pubmedcentralcanada.ca)
  • Cladribine (also known as 2-chlorodeoxyadenosine, 2-CDA) is an adenosine deaminase-resistant 2-deoxypurine nucleoside analog which requires phosphorylation by deoxycytidine kinase. (biomedcentral.com)
  • Your doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with cladribine and each time you refill your prescription. (medlineplus.gov)
  • Before you begin treatment with cladribine, you and your doctor should talk about the good cladribine will do as well as the risks of using it. (drugs.com)
  • however, severe neurological toxicity has been reported rarely following treatment with standard cladribine dosing regimens. (drugs.com)
  • When you are taking cladribine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. (drugs.com)
  • Using cladribine with any of the following medicines is not recommended. (drugs.com)
  • Using cladribine with any of the following medicines is usually not recommended, but may be required in some cases. (drugs.com)
  • Cladribine is currently being appraised by the Scottish Medicines Consortium (SMC) and we are contributing to the appraisal. (mstrust.org.uk)
  • For cladribine medicines with oncology indications (Litak and Leustat), the product information for healthcare professionals and patients is being updated and a letter has been sent to haematologists and oncologists about the risk. (www.gov.uk)
  • Cladribine should not be used in combination with some biologic or immunologic medicines, while other combinations will require careful monitoring. (emedtv.com)
  • Cladribine may decrease the effectiveness of sipuleucel-T . Talk to your healthcare provider about this potential interaction before using these medicines together. (emedtv.com)
  • Cladribine injection should be administered under the supervision of a qualified physician experienced in the use of antineoplastic therapy. (drugs.com)
  • Following completion of the 2 treatment courses (after year 2), no further cladribine treatment is required in years 3 and 4. (thesocialmedwork.com)
  • Following completion of the 2 treatment courses, no further cladribine treatment is required in years 3 and 4. (healthdirect.gov.au)
  • Immunophenotyping studies show that cladribine depletes lymphocyte populations in vivo with a predilection for B cells. (nih.gov)
  • 500/mm3), and estimate that less 7% of cladribine treated subjects will develop lymphocyte counts less than 500/mm3 if we stick to the cladribine redosing guidelines. (multiple-sclerosis-research.org)
  • A total of 24 patients (median Expanded Disability Status Scale (EDSS) of 4.5) received cladribine (0.07 mg/kg/day) for four consecutive days every six months for ≥ 2 cycles ( 0.56mg/kg per year which is abit lower that the oral variant equivalent) with further cycles depending on lymphocyte recovery or disease activity to a maximum of eight cycles from 2005 until 2016 were included. (multiple-sclerosis-research.org)
  • Nerve damage may occur more than one month after cladribine injection is given. (medlineplus.gov)
  • Cladribine injection comes as a solution (liquid) to be injected intravenously (into a vein) by a doctor or nurse in a medical facility. (medlineplus.gov)
  • Cladribine comes as a solution that's given as an injection via an IV and is administered only by a qualified healthcare specialist. (healthery.com)
  • No treatment has achieved a high complete remission (CR) rate even in small series, and of 39 reported cases from six studies, overall response rate after cladribine was 44% with 8% CRs. (nih.gov)
  • Localized radiation therapy to both proximal femurs and subsequently 4 weeks later, a 7-day course of 0.1 mg/kg/day cladribine provided complete remission with relief of symptoms and resolution of bone lesions. (hindawi.com)
  • Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. (druglib.com)
  • cladribine is a topic covered in the Davis's Drug Guide . (drugguide.com)
  • Davis's Drug Guide - OLD - USE 2.0 , www.drugguide.com/ddo/view/Davis-Drug-Guide/51158/all/cladribine. (drugguide.com)
  • Your doctor will order certain tests before, during, and after treatment to check your body's response to cladribine. (medlineplus.gov)
  • Because cladribine can decrease the body's immune response, you could become infected with the virus or bacteria used to make the vaccine. (emedtv.com)
  • Patients with the CD25-negative variant (HCLv) respond poorly to initial cladribine but do respond to rituximab in anecdotal reports. (clinicaltrials.gov)
  • In studies with limited follow-up, MRD detected by tests other than RQ-PCR can be eliminated by rituximab after cladribine in greater than 90 percent of patients, but MRD rates after cladribine alone are unknown. (clinicaltrials.gov)
  • Simultaneous cladribine and rituximab might be superior or inferior to delaying rituximab until detection of MRD. (clinicaltrials.gov)
  • To determine if HCL MRD differs at 6 months after cladribine with or without rituximab administered concurrently with cladribine. (clinicaltrials.gov)
  • To evaluate the effects of cladribine and rituximab on normal T- and B-cells. (clinicaltrials.gov)
  • Non-randomized arm: 20 with HCLv will begin rituximab with cladribine. (clinicaltrials.gov)
  • Rituximab has been found to increase the sensitivity of malignant cells to cladribine, suggesting that combination with cladribine might improve response in HCLv. (nih.gov)
  • To test this hypothesis, patients with HCLv were treated with simultaneous cladribine and rituximab. (nih.gov)
  • Although cladribine alone lacks effectiveness for early or relapsed HCLv, cladribine with immediate rituximab achieves CRs without MRD and is feasible to administer. (nih.gov)
  • From January 2000 to February 2001, 16 patients (15 male, 1 female) with HCL,with a median age of 57 years (range: 38-81 years), having relapsed afterprior treatment with cladribine, were treated with rituximab (Rituxan) at 375mg/m² weekly × 4. (cancernetwork.com)
  • CONCLUSION: Rituximab, administered at this dose and schedule, has onlymodest activity in cladribine-failed HCL patients when compared to other agentsactive in this disease. (cancernetwork.com)
  • Actually, the norwegian government is refusing to make an agreement with Roche on Ocrevus because they don't see any added value over Rituximab/ MabThere, so I am surprised they are not taking the same route for Cladribine. (multiple-sclerosis-research.org)
  • This phase II trial studies how well venetoclax , cladribine, low dose cytarabine, and azacitidine work in treating patients with acute myeloid leukemia that has previously not been treated. (clinicaltrials.gov)
  • Giving venetoclax , cladribine, low dose cytarabine induction followed by cladribine, low dose cytarabine, and azacitidine consolidation may work better in treating patients with acute myeloid leukemia. (clinicaltrials.gov)
  • I. To assess the complete response (CR/complete response with incomplete recovery [CRi]) rate of patients with acute myeloid leukemia (AML) treated with venetoclax combined with cladribine (2-CDA) plus low-dose cytarabine (LDAC) alternating with 5-azacytidine (AZA). (clinicaltrials.gov)
  • The therapeutic role of cladribine against diffuse large B-cell lymphoma cells (DLBCL) is still undefined. (omgcb.com)
  • At least 1% of people using Cladribine have reported the following side effects. (healthery.com)
  • Also, live vaccines may be less effective in people using cladribine. (emedtv.com)
  • The neutropenia resolved after 20 days of cladribine monotherapy. (kjim.org)
  • It is recommended that administration of any other oral medicinal product be separated from that of cladribine by at least 3 hours during the limited number of days of cladribine administration. (thesocialmedwork.com)
  • The trials examining the role of cladribine in MS were analyzed. (thisisms.com)
  • Also, we showed that suberoylanilide hydroxamic acid (SAHA) enhanced the pro-apoptotic role of cladribine. (omgcb.com)
  • Stratification: 68 patients with 0 and 62 with 1 prior course of cladribine. (clinicaltrials.gov)
  • In addition, opportunistic viral infections are common during the month after cladribine therapy and appropriate vaccination is recommended before its use. (wikimd.org)
  • Recent data suggest that cladribine may have a role in the treatment of relapsing-remitting and the progressive forms of MS. In these studies, cladribine has shown mixed results in decreasing neurologic disability, as measured by various rating scales, but has consistently shown positive results in reducing the number of enhancing lesions, which reflects a measure of disease activity. (thisisms.com)
  • When and where the rate of SARS-CoV2 infection is very high, the risks of increased infection for three months after cladribine administration, and the advice to shield, may outweigh its benefits . (multiple-sclerosis-research.org)
  • In patients treated with parenteral cladribine for oncologic indications, cases of progressive multifocal leukoencephalopathy (PML) have been reported in the postmarketing setting. (mavenclad.com)
  • An alternative to this medication should be prescribed or you should stop breastfeeding while using cladribine. (drugs.com)
  • Cladribine may also be used for purposes not listed in this medication guide. (cigna.com)
  • Cladribine is a cancer medication that interferes with the growth and spread of cancer cells in the body. (rxlist.com)
  • Do not use cladribine if you are allergic to cladribine or any ingredients of the medication. (pharmasave.com)
  • In the case of cladribine, there are no specific foods that you must exclude from your diet when receiving this medication. (rxwiki.com)
  • Cladribine is a potent medication that can cause significant and potentially life-threatening side effects. (emedtv.com)
  • Cladribine is a pregnancy Category D medication, which means it may harm an unborn child if used during pregnancy. (emedtv.com)
  • Reported known side effects oral medication cladribine include increased chance of infection, fatigue, and anemia. (yuptab.com)
  • Now if you run cladribine or alemtuzumab against natalizumab in a head-2-head study and used NEDA as an outcome I suspect natalizumab will win. (blogspot.com)
  • Alemtuzumab and cladribine tablets also produce prolonged depletion after two courses. (activemsers.org)
  • Alemtuzumab may produce greater depletion of both CD4+ and CD8+ T cells than cladribine tablets, although both treatments similarly deplete B cells. (activemsers.org)
  • Because cladribine and alemtuzumab are classified as immune reconstitution therapies (IRTs), and probably work in a similar way, they are tarnished with the same brush. (multiple-sclerosis-research.org)
  • Patients should be informed if their treatment choice requires shielding [especially cladribine and alemtuzumab] . (multiple-sclerosis-research.org)
  • Against cladribine is that the relative efficacy of the drug puts it in the same ball-park as that of fingolimod and daclizumab and not natalizumab, alemtuzumab or ocrelizumab. (blogspot.ie)
  • However the NEDA rate for cladribine in the pivotal trial was lower than that found with alemtuzumab. (multiple-sclerosis-research.org)
  • Your doctor may tell you not to take cladribine. (medlineplus.gov)
  • Do not take cladribine if you are pregnant or plan to become pregnant. (medlineplus.gov)
  • Take cladribine at around the same time every day. (medlineplus.gov)
  • Take cladribine exactly as directed. (medlineplus.gov)
  • Do not take cladribine if you are pregnant. (cigna.com)
  • Tell your doctor if you have recently received a vaccine (within 4 to 6 weeks before you take cladribine). (cigna.com)
  • A recent European review was triggered by post-marketing reports of progressive multifocal encephalopathy (PML) in patients given cladribine for haematological cancer. (www.gov.uk)
  • So far this is associated with the use of the generic cladribine, probably in cancer, rather than oral variant in MS. It says there have been three cases. (blogspot.com)
  • Finally, cladribine resistance may be a consequence of a defective induction of apoptosis. (diva-portal.org)
  • and Xu, Kailin, "Suberoylanilide hydroxamic acid (SAHA) and cladribine synergistically induce apoptosis in NK-LGL leukaemia" (2014). (pcom.edu)
  • It also activated endoplasmic reticulum (ER) stress, and ATF4 expression was required for cladribine induced apoptosis. (omgcb.com)
  • Apoptosis assays with Annexin V-FITC/PI double staining indicated that cladribine induced apoptosis of U266 cells in a dose-dependent manner. (biomedcentral.com)
  • Similar results were obtained with an apoptotic-ELISA showing that cladribine dramatically promoted MM1.S and RPMA8226 cells undergoing apoptosis. (biomedcentral.com)
  • The combinations of cladribine and a specific STAT3 inhibitor as compared to either agent alone significantly induced apoptosis in all three MM cell lines. (biomedcentral.com)
  • MM1.S is the only cell line showing significant response to the clinically achievable concentrations of cladribine-induced apoptosis and inactivation of STAT3. (biomedcentral.com)
  • Using cladribine together with clofarabine may increase the risk of serious infections. (drugs.com)
  • Investigators have discovered that clofarabine and cladribine may be used as a targeted therapy in diseases where CD99 plays a critical role, including Ewing sarcoma and auto-immune disorders. (cancernetwork.com)
  • First, clofarabine and cladribine can be used as a targeted therapy for additional malignancies where CD99 plays a critical role, the most important of which is Ewing sarcoma. (cancernetwork.com)
  • Cladribine interferes with the growth of cancer cells, which are eventually destroyed. (drugs.com)